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1. ABSTRACT 
 
CD47 activation by peptides derived from the C-terminal domain of thrombospondin-1, such 
as PKHB1, induces regulated cell death (RCD) in different types of cancer cells. The RCD 
induced by the activation of CD47 is characterized by being independent of caspases, calcium 
dependent, generating morphological changes in the endoplasmic reticulum (ER) and the 
exposure of calreticulin (CRT) in chronic lymphocytic leukemia (CLL) cells. On the other 
hand, ER stress and CRT exposure are characteristics of immunogenic cell death (ICD). 
Based on the above, the objective of this thesis was to determine the immunogenicity of cell 
death induced by the activation of CD47 in lymphoma and breast cancer cells. To this end, 
ICD’s characteristics were evaluated, such as damage associated molecular patterns 
(DAMPs) exposure or release and their effect on the activation of an antitumor immune 
response. In addition, the extent of the immunogenicity of death was evaluated by 
prophylactic and therapeutic vaccinations, with lysates of cancer cells treated with PKHB1 
(PKHB1-TCL) on the tumor establishment of lymphoma and breast cancer (in vivo), as well 
as their capacity to generate a long-term anti-tumor immunological memory. 
The results obtained allow us to demonstrate that PKHB1 induces CRT exposure and release 
of CRT and HSP90 in lymphoma and breast cancer cells. It was also demonstrated that the 
PKHB1-TCL promotes the maturation of dendritic cells (DCs) increasing the expression of 
maturation markers CD80, CD86 and the release of TNFa. Furthermore, the PKHB1-TCL 
activated the antitumor immune response (ex vivo), promoting the specific cytotoxicity of 
tumor cells by T lymphocytes and induced the inflammatory cytokines IL-2 and IFNg release. 
Finally, it was demonstrated that the PKHB1-TCL is able to prevent the tumor establishment 
in a lymphoma and murine breast cancer model, and to induce a long-term immunological 
anti-tumor memory. 
Finally, when observing that the immunogenic characteristics of death are shared among the 
different tumor models, we can propose that the CD47 activation by PKHB1 induces a 
conserved ICD mechanism, enhancing its application and making it a promising antitumor 
therapy.  
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2. RESUMEN 
La activación de CD47 por péptidos derivados del dominio C-terminal de la trombospondina-
1, como el PKHB1, induce muerte celular regulada (MCR) en diferentes tipos de células 
cancerosas. La MCR inducida por la activación de CD47 se caracteriza por  ser independiente 
de caspasas, dependiente de calcio, generar cambios morfológicos en el retículo 
endoplásmico (RE) y exposición de Calreticulina (CRT) en células de leucemia linfocítica 
crónica (LLC). El estrés del RE y la exposición de CRT son característias de la muerte celular 
inmunogénica (MCI). Con base en lo anterior, el objetivo de esta tesis fue determinar la 
inmunogenicidad de la muerte celular inducida por la activación de CD47 en células de 
linfoma y cáncer de mama. Para ello se evaluaron características de MCI, como la liberación 
de patrones moleculares asociados a daño (DAMPs) y su efecto en la activación de la 
respuesta inmune antitumoral. Además, se evaluó el alcance de la inmunogenicidad de la 
muerte mediante vacunaciones profilácticas y terapéuticas, con lisados de células cancerosas 
tratadas con PKHB1 (PKHB1-TCL) sobre el establecimiento tumoral de linfoma y cáncer de 
mama (in vivo), así como su capacidad de generar una memoria inmunológica antitumoral a 
largo plazo.  
Los resultados obtenidos nos permiten demostrar que el PKHB1 induce la exposición de CRT 
y liberación de CRT, HSP90, ATP y HMGB1 en células de linfoma y cáncer de mama. 
También se demostró que el PKHB1-TCL promueve la maduración de células dendríticas 
(DCs) aumentando la expresión de marcadores de maduración CD80, CD86 y la liberación 
de TNFa. Asimismo, el PKHB1-TCL activó la respuesta inmune antitumoral (ex vivo), 
promoviendo la citotoxicidad específica de células tumorales por linfocitos T e indujo la 
liberación de citocinas inflamatorias IL-2 e IFNg. Además, se demostró que el PKHB1-TCL 
es capaz de prevenir y disminuir el establecimiento tumoral hasta lograr la remisión en un 
modelo de linfoma y cáncer de mama murino, además de inducir una memoria inmunológica 
antitumoral a largo plazo. 
Finalmente, al observar que las características inmunogénicas de la muerte se comparten 
entre los diferentes modelos tumorales, podemos proponer que la activación de CD47 por el 
PKHB1 induce un mecanismo conservado de MCI, potenciando su aplicación y haciéndola 
una prometedora terapia antitumoral.  
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3. INTRODUCTION 
 
CD47 is an ubiquitously expressed transmembrane receptor, member of the immunoglobulin 
superfamily, with diverse functions in the immune system. It is a counter-receptor for the 
signaling protein alpha (SIRPα) and also acts as a receptor for thrombospondin-1 (TSP1). 
CD47 acts as a “don’t eat me” signal when interacting with SIRPα, a receptor that is highly 
expressed in professional phagocytes, such as macrophages and dendritic cells, which 
regulates programed cell removal (Matozaki et al. 2009). The interaction of CD47 with the 
C-terminal domain of TSP1 or peptides derived from this domain (such as 4N1K and 
PKHB1) regulates distinct cellular activities, such as cell-cell interactions, migration, 
proliferation and death, depending on the cellular context. It has been observed that the TSP1-
CD47 interaction induces regulated cell death (RCD) in different types of cancer cells 
(Denèfle et al. 2016a). In chronic lymphocytic leukemia (CLL) cells PKHB1 induces 
calreticulin (CRT) exposure on the cell surface (A. C. Martinez-Torres et al. 2015). CRT is 
an ER chaperone protein that can be exposed to the cell membrane under conditions of ER 
stress. When it is exposed, it functions as an “eat me” signal with a crucial role in the 
immunogenicity of cell death, favoring the activation of an anti-tumor immune responses 
(Obeid et al. 2007).  
Immunogenic cell death (ICD) has been recently recognized as a critical determinant for the 
efficiency of cancer therapy, since it is a cell death modality that is capable of stimulating an 
immune response against dead cell antigens, particularly when they are derived from cancer 
cells. The ICD is characterized by the exposure and release of damage associated molecular 
patterns (DAMPs) such as; CRT, heat shock proteins (HSP70 and 90), ATP and HMGB1 
(Garg et al. 2015). 
In recent years, distinct immunogenic cell death inductors have been discovered, including 
conventional chemotherapeutics, oncolytic viruses, targeted antitumor agents and other 
biological and physicochemical therapies. However, it has been observed that although 
different treatments can induce the DAMPs exposure and release in vitro, its application in 
cancer patients is not always efficient (Kepp et al. 2014). Thus, to conclude that a certain 
drug is an ICD inducer the analysis of DAMPs should be complemented by ex vivo and in 
vivo analyses of the antitumor immune responses (Garg et al. 2015). Therefore, the 
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vaccination assays are the “gold standard” that prove the ability to reject tumors in 
immunized hosts (Garg et al. 2015).  
Due to the importance of ICD in the efficacy of antitumor therapies, the activation of CD47 
by agonist peptides such as PKHB1 is an attractive strategy for the induction of ICD, since 
the activation of CD47 by PKHB1 induces ER morphological changes and CRT exposure in 
CLL, two main characteristics of the ICD. 
For all the above, this thesis work was focused in the evaluation of the immunogenicity of 
cell death induced by the activation of CD47 in different types of tumor cells. 
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4. BACKGROUND 
 
4.1 Cell death 
Every day our cells carry out endless processes that are necessary for the maintenance and 
the proper functioning of the organism. Within these processes is the death per se of the cells, 
especially of the cells with physical damage, infected with pathogenic agents or carrying 
genetic alterations, which prevent them from maintaining their functions. Cell death can be 
carried out in different ways, which unleashes ambiguities when describing the pathways 
through which the cell dies. From a conceptual point of view, cell death can be defined as 
the permanent cessation of vital cellular functions. However, for the precise identification of 
a dead cell the Cell Death Nomenclature Committee (NCCD) has proposed the following 
three criteria: 
 
1. The permanent loss of the barrier function of the plasma membrane. 
2. The breakdown of the cell into discrete fragments (apoptotic bodies). 
3. Immersion of the cell by professional phagocytes or other cells with phagocytic activity 
(L Galluzzi et al. 2012).  
 
Currently the NCCD classifies cell death into two broad categories, described below and 
schematized in Figure 1: 
Accidental cell death (ACD) 
A type of almost immediate death, caused by physical (high temperatures or pressures), 
chemical (powerful detergents or variations in pH) or mechanical damage, insensitive to 
pharmacological or genetic interventions of any kind. 
Regulated cell death (RCD) 
It involves a genetically encoded molecular machinery; therefore, it can be altered 
pharmacologically or genetically, using as a target the key components of this machinery. 
RCD often occurs due to the failed attempts of the cell to restore homeostasis. 
It should be noted that RCD does not occur exclusively as a consequence of 
microenvironmental disturbances, but also in the context of embryonic development, tissue 
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homeostasis, and immune response. Such completely physiological cases are generally 
referred to as programmed cell death (L Galluzzi et al. 2012). 
 
4.1.1 Programed cell death (PCD) 
It is an evolutionarily conserved pathway for embryonic development and tissue homeostasis. 
PCD acts as a normal physiological response to different stimuli that leads to the elimination 
of abnormal cells, infected or unable to perform their functions correctly (Sjostrom 2001). 
 
 
 
 
 
 
 
 
 
 
 
Figure. 1 Types of cell death. Cells exposed to physical, chemical and mechanical extreme stimuli 
succumb in a completely uncontrollable way of cell death, with the immediate loss of structural 
integrity. This type of death is known as: accidental cell death (ACD). On the other hand, cell death 
can be initiated by a genetically encoded machinery, this death is called regulated cell death (RCD). 
The term programmed cell death (PCD) is used to indicate cases of RCD that occur as part of a 
developmental program or to preserve adult tissue homeostasis. 
 
Table 1 shows different RCD modalities classified biochemically, according to the 
dependence on caspases. Caspases are cysteine proteases that hydrolyze peptide bonds and 
can also generate signaling molecules that participate in different processes, such as regulated 
cell death.  
  
CELL DEATH
SUBTYPES
REGULATED 
CELL DEATH
PROGRAMMED 
CELL DEATH
ACCIDENTAL
CELL DEATH
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Table 1. Modalities of regulated cell death 
 
Adapted from (Martínez-Torres 2013; and Galluzzi et al. 2018). 
 
5. Deregulation of cell death and associated pathologies 
 
Cell division and death are predominant physiological processes that regulate tissue 
homeostasis in the body. Deregulation of these processes are involved in the pathogenesis of 
diseases, such as neurodegenerative disorders, myocardial infarction, cerebrovascular 
accidents, atherosclerosis and cancer (the most important group of diseases for this thesis 
work). Therefore, attempts to find cell cycle and cell death modulators are being made with 
Modalities of Regulated Cell Death
Types of Cell Death Subtypes/Triggers Main Features
Caspase-
Dependent
Extrinsic Apoptosis
Cell death receptors (FAS, TNFR)
Dependent Receptors (DCC or UNC5B when
its ligan netrin-1 is missing)
Initiated by perturbations of the extracellular 
microenvironment. Need caspase 8 and 
Caspase 3.
Intrinsic Apoptosis
Mediated by:
DNA damage
Oxidative stress 
ER stress
RCD initiated by perturbations of the 
extracellular or intracellular 
microenvironment, demarcated by MOMP, 
and need executioner caspases
Atypic cases
Anoikis:  lack of external membrane signal-
dependent
Specific variant of intrinsic apoptosis 
initiated by the loss of integrin-dependent 
anchorage and some grown factor like EGFR
Cornification
Ocurrs in the epidermis and involves the
activation of transglutaminases
Pyroptosis: formation of plasma membrane 
pores by members of the gasdermin protein 
family,often as a consequence of inflammatory 
caspase activation.
RCD Caspase 1-dependent. Display
morphologics characteristics of both
apoptosis and necrosis
Lysosome-dependent cell death
Demarcated by lysosomal membrane 
permeabilization
and precipitated by cathepsins, with optional 
involvement of MOMP and caspases.
Caspase-
Independent
Autophagy
A massive vacuolization of the citoplasm; 
trigger by innanition or stress
Induce lipidation MAP1LC3 and degradation
of SQSTM1
Regulated Necrosis
Necroptosis: triggered by perturbations of 
extracellular or intracellular homeostasis 
Depends on MLKL,RIPK3, and (at least in 
some settings) on the kinase activity of 
RIPK1.
Parthanatos
Initiated by PARP1 hyperactivation and 
precipitated by the consequent bioenergetic 
catastrophe coupled toAIF-dependent and 
MIF-dependent DNA degradation.
Mitochondrial permeability transition 
(MPT)-driven necrosis: RCD triggered by 
perturbations of the intracellular 
microenvironment
Generally manifests with a necrotic 
morphotype and relying on CYPD.
Mitotic catastrophe
and Mitotic death
Oncosuppressive mechanism for the control of 
mitosis-incompetent cells by RCD
Per se, mitotic catastrophe does not 
constitute a form or RCD.
Atypic cases
NETotic cell death
A ROS-dependent modality of RCD 
restricted to cells of hematopoietic derivation 
and associated with NET extrusion.
Entotic cell death
is a form of cell cannibalism that occurs in 
healthyand malignant mammalian tissues
A type of RCD that originates from 
actomyosin-dependent cell-in-cell 
internalization (entosis) and is executed by 
lysosomes. 
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the hope of creating new therapeutic approaches to treat these diseases. It is clear that a better 
understanding of how cells balance the life and death processes is crucial for this 
development. 
Furthermore, the deregulation in the cell death machinery can result in death resistance, 
which is associated with carcinogenesis. In fact, the resistance to cell death is one of the 10 
hallmarks of cancer cells, as well as one of the principal targets of anti-cancer therapies 
(Hanahan and Weinberg 2011). 
 
6. Resistance to cell death in cancer 
 
Tumor cells develop different strategies to limit or elude apoptosis. The most common is the 
loss of function of the tumor suppressor protein (p53), alternatively, tumors can achieve 
similar purposes by increasing the expression of antiapoptotic regulators (Bcl-2, Bcl-x) or 
survival signals (Igf1 / 2), by negatively regulating proapoptotic factors (Bax, Bim, Puma) 
or by blocking the extrinsic pathway of ligand-induced death (Hanahan and Weinberg 2011). 
The structure of the RCD machinery and the strategies used by cancer cells to evade their 
functions, reflects the diversity of cancer cell populations during their evolution to the 
malignant state (Zhivotovsky and Orrenius 2010). 
 
7. Emerging therapies: the immunogenicity of cancer cells 
 
Every day, several millions of cells succumb to mechanisms of regulated cell death, and these 
cells are eliminated efficiently without causing local or systemic inflammation. This 
homeostatic cell death, that mainly occurs by apoptosis, is considered to be tolerogenic 
(promoting tolerance towards one's own) or as a null effect without impact on the immune 
system (Kroemer et al. 2013). 
However, for some years now we have witnessed the appearance of a new concept; 
Immunogenic cell death (Kroemer et al. 2013), that is, a cell death modality that stimulates 
an immune response against antigens of dead cells, particularly when they are derived from 
cancer cells. This model was proposed for the first time in the context of anticancer 
chemotherapy, based on clinical evidence that indicates that tumor-specific immune 
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responses can determine the effectiveness of anti-cancer therapies with conventional 
cytotoxic drugs (Kroemer et al. 2013; Showalter et al. 2017).  
For this reason, the immunogenicity of dying cancer cells to improve the efficacy of cancer 
therapy is a paradigm that has gained significant impulse in the last 5 years (Garg et al. 2015). 
 
8. Immunogenic cell death: a new paradigm 
 
The most notable advances in anti-cancer therapies involve different forms of cell death that 
broaden the scope of the classical cell death modalities, such as apoptosis, through the use of 
new cytotoxic agents (Hanahan and Weinberg 2011).  
Classical cancer regimens induce cancer cell death mainly through apoptosis, a cell death 
process that has generally been considered immunosuppressive or even tolerogenic. 
However, recently it has emerged a selected class of cytotoxic agents (for example, 
anthracyclines) that can induce an immunogenic form of apoptosis in tumor cells, through 
the emission of distinct damage associated molecular patterns (DAMPs) and thus, these 
dying tumor cells can induce an effective antitumor immune response (Krysko et al. 2012).  
Extensive studies have revealed two different types of immunogenic cell death (ICD) 
inductors, classified according to their form of inducing stress in the endoplasmic reticulum 
(ER). Importantly, ICD inductors are able to restart the immune responses that are usually 
suppressed by the tumor microenvironment (Inoue and Tani 2014).  
For this reason, the anti-cancer emerging therapies focus on the induction of immunogenic 
cell death (which will be described below) in order to favor the tumor elimination and prevent 
their possible recurrence, through the anti-tumor immunological memory establishment. 
 
8.1 Immunogenic cell death and cancer 
 
The immunogenicity of cancer cells has been recognized as a critical determinant in the anti-
cancer therapies. Therefore, in addition to developing direct immunostimulatory regimens, 
which include dendritic cell-based vaccines, cancer checkpoint blocking therapies and 
adoptive T cell transfer, researchers have begun to focus on the general immunobiology of 
neoplastic cells (Kroemer et al. 2013). Now it is clear that cancer cells may succumb to some 
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anti-cancer therapies in a peculiar form of cell death that is characterized by an increased 
immunogenic potential, due to the emission of DAMPs. The emission of DAMPs by cells 
that succumb to ICD favors the establishment of a productive connection with the immune 
system (Kroemer et al. 2013). 
It has also been shown that the induction of cancer cell death pathways associated with the 
pre-mortem emission of DAMPs, considerably increase the immunogenicity of these dying 
cells (Kepp et al. 2014), and can result in the activation of anti-tumor immune responses 
(Garg et al. 2015). 
 
8.2 Damage associated molecular patterns (DAMPs)   
 
DAMPs are intracellular molecules that are not recognized by the immune system under 
normal physiological conditions. However, under conditions of cellular stress or tissue 
injury, these molecules are passively released into the extracellular environment by dying 
cells, thus allowing their binding to receptors in immune cells. It is noteworthy that the 
DAMPs can have pro and anti-inflammatory effects, as well as chemotactic, mitogenic and 
tissue remodeling effects depending on the context in which they are recognized by the host 
(Land 2015). Table 3 summarizes the most outstanding DAMPs characterized to date and 
their mode of emission, the cell death path to which they are associated and their related 
receptors (Garg et al. 2015).  
On the other hand, it is important to consider that not all DAMPs can act as immunogenic 
warning signs. As shown in Table 2, there are several DAMPs that are crucial for the 
maintenance of tissue homeostasis and the repression of autoimmune responses, since they 
exert immunosuppressive effects, including Annexin A1 (ANXA1), death domain 1α 
(DD1α) and some molecules derived from the extracellular matrix (Garg et al. 2015).  
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Table 2. Prominent damage-associated molecular patterns (DAMPs) associated in 
immunogenic cell death
 
Adapted from (Garg et al. 2015; Lorenzo Galluzzi et al. 2017) 
 
The principal DAMP associated with ICD is calreticulin (CRT), which is normally located 
in the light of the ER, but when it is exposed to the plasma membrane it has been shown to 
function as a potent “eat me” signal, allowing the phagocytosis of stressed or dying tumor 
cells by dendritic cells (DCs) (Garg et al. 2015). In addition, CRT is able to stimulate the 
production of IL-6, tumor necrosis factor (TNFa) and improves the antigen presentation to 
T lymphocytes by DCs, facilitating the polarization of Th1 lymphocytes (lymphocytes that 
activate macrophages, dendritic cells and NK cells). For this reason, CRT is the main protein 
of immunogenic cell death (Garg et al. 2015). 
 
The high mobility group 1 protein (HMGB1) is a non-histone chromatin binding protein that 
influences transcription and other nuclear functions (Tesniere et al. 2008), which, once 
present in the extracellular space, can act as a signal of tissue damage and initiate an 
inflammatory response through binding to a range of receptors, including the receptor for 
DAMPs Receptors
Localization and
mode of emission
Relevant cell
death pathway
Functions
Annexin A1 FPR-1
Surface exposed or
actively
Apoptosis
Guides the final approach of APCs
to dying cells
Adenosine
Triphosphate
P2Y2 and
P2Y7
Actively or passively
released
ICD, Apoptosis /
Necrosis
Favours the recruitment of APCs and
their activation
Calreticulin LPR1 (CD91)
Mostly surface
exposed
sometimes passively
released
ICD
Promotes the uptake of dead cell-
associated antigens
Cellular RNA,
dsRNA, ssRNA,
dsDNA
TLR3, TLR7,
CDSs
Passive release ICD/Necrosis
Promotes the synthesis of pro-
inflammatory factorsincluding type I
IFNs
Type I IFNs IFNAR - ICD
Promote CXCL10secretion by
cancercells and exert
immunostimulatory effects
Thrombospondin 1
and its heparin-
binding domain
αvβ3 integrin Passively released or
surfaceassociated
Apoptosis
Mediates the protein’s interaction
with calreticulin, and integrins
during cellular adhesion. Low-
density lipoprotein receptor-related
protein during uptake and clearance
Heat shock
proteins
(HSP70/90,60,72)
LRP1,TLR2,
TLR4 SREC-1
and FEEL-1
Surface exposure,
active secretion or
passive release
ICD, Apoptosis /
Necrosis
Stimulates the uptake of dead cell-
associatedantigens
High-mobility
group box
TLR2, TR4,
RAGE and TIM3
Mostly passively
relesed; sometimes
actively released
ICD/Necrosis
Promotes the synthesis of pro-
inflammatory factorsincluding type I
IFNs
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advanced glycosylation end products (RAGE), and toll like receptors (TLR2 or TLR4) on 
DCs (Tesniere et al. 2008). When bound to these receptors it activates the production of 
proinflammatory cytokines and it participates in the correct antigen presentation. In addition, 
it has been found that extracellular HMGB1 suppresses the activity of immunosuppressive 
cells such as regulatory T lymphocytes (Garg et al. 2015).  
 
Extracellular ATP is a potent short-range "find me" signal (Elliott et al. 2009), it promotes 
the immune cells recruitment at ICD sites and their differentiation, this effect depends on the 
P2Y purinergic receptor (coupled to a G protein). Extracellular ATP also promotes the 
activation of DCs (Ghiringhelli et al. 2009), causing the activation of the NLRP3 
inflammasome and proinflammatory cytokines release such as IL-1β and IL-18 (Garg et al. 
2015).  
 
On the other hand, heat shock proteins (HSP) 70 and 90 have also been found on the cell 
surface during ICD (Showalter et al. 2017). During the tumor cell death, HSP70 and HSP90 
can be transferred to the plasma membrane to facilitate the uptake and processing of dead 
tumor cells’ antigens by DCs and to present "cross-linked" peptides derived from tumors to 
CD8 + T cells, which leads to a cytotoxic response. The HSPs exposure takes place relatively 
late compared to CRT and could therefore play a secondary role (with CRT being the primary 
"eat me" signal) in the decision for antigen taking and processing by CD (Kepp et al. 2011). 
 
Overall, the exposure of the proteins described above (as well as ATP) is crucial for the 
immunogenicity of dead cancer cells, Figure 2 shows a diagram of how the main DAMPs are 
implicated in ICD (Garg et al. 2015). 
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Figure 2. DAMPs implication on ICD. Cancer cells responding to ICD inducers by the exposure and 
release of CRT, HSP70/HSP90, ATP and HMGB1. Consequently, these DAMPs interact with 
receptors on immature DCs such as CRT,HSP90,HSP70-CD91 stimulating the absorption of dying 
tumor cells and/or their corpses (apoptotic bodies), ATP-P2X7 resulting in the assembly and 
activation of the NLRP3 inflammasome and thus in the secretion of IL-1β, HMGB1-TLR4 inhibits 
the degradation pathway of the lysosomal antigen in dendritic cells (which favors the processing and 
presentation of the tumor antigen) and stimulates the synthesis of the interleukin 1β precursor (Pro-
IL-1β), and with unknown surface molecules. These DAMPs cause maturation of DCs, characterized 
by cell-surface upregulation of MHC-II, CD86, CD83, and CD80 and a distinctly pro-inflammatory 
cytokine pattern as indicated. Adapted from (Kepp et al. 2011; Hou et al. 2013). 
 
 
8.3 Immunogenic capacity of treatments 
 
Some anti-tumor therapies used with success for decades (chemotherapy and radiotherapy) 
can cause immunogenic cell death, however defects in the immune system involved with the 
ability to perceive a cell death as immunogenic, influence negatively among cancer patients 
treated with ICD inductors (Kepp et al. 2014).  
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Among different DAMPs, the CRT exposure is presented universally for all ICD inductors, 
therefore it is the most important DAMP, while ATP, HMGB1 or HSP70/90 may or not be 
present in certain ICD contexts. Therefore, only the analysis of molecular determinants is not 
reliable for the ICD characterization. For this purpose, the analysis of ICD-DAMPs should 
be considered secondary to the in vivo and/or ex vivo immunological analysis of the antitumor 
immune response, to conclude that a certain drug is an ICD inducer (Garg et al. 2015). Figure 
3 shows the antitumor immune system establishment by the ICD. For this reason, the gold 
standard for evaluating the ability of a specific agent or modality to cause ICD is based on 
vaccination trials that show tumor rejection capabilities of the immunized host (Garg et al. 
2015).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Establishment of the antitumor immune response by ICD. The induction of ICD leads to the 
recruitment of dendritic cells, then the apoptotic bodies are phagocytosed, and the antigens derived 
from tumors are processed and presented together with MHC and costimulatory molecules, after the 
maturation of DCs, to naive T lymphocytes. This process can be amplified in different steps. The 
selection of ICD inducers allows to improve the recognition and phagocytosis of the apoptotic 
residues, the maturation of DCs, the processing and the presentation of antigens derived from tumors. 
This leads to the establishment of the cytotoxic immune response, which involves CD4 + and CD8 + 
T lymphocytes, resulting in the complete eradication of the tumor cells. Adapted from (Tesniere et 
al. 2008). 
 
In this context, as described in Figure 4, the cancer cells are treated in vitro with the 
drug/agent/modality/therapy to be evaluated and then the tumor cell lysate obtained after 
  15 
treatment, is injected subcutaneously/intradermally in the flank of immunocompetent 
syngeneic mice. Seven days later, this treatment is followed by a new challenge with living 
cells of the same type of cancer in the opposite flank or another site of choice for the tumor. 
The proportion of mice that resist to the tumor establishment reveals the degree of 
immunogenicity of cell death for the evaluated therapy (Garg et al. 2015; Kepp et al. 2014).  
These rigorous standards, if maintained, would allow adequate characterization of the new 
ICD inducers while eliminating the possibility of false positives (Garg et al. 2015).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Operational definition of ICD. The death of cancer cells can be defined as immunogenic, 
based on the prevention of tumor establishment. The injection of cancer cells that succumb to ICD in 
immunocompetent mice should elicit a protective immune response that is specific for tumor 
antigens, in the absence of any adjuvant. Adapted from (Kroemer et al. 2013). 
 
It is of great importance for ICD research to determine if other pathways of cell death could 
be associated in the generation of immunological memory against tumors, especially drugs, 
molecules, antibodies, peptides (among others) that are associated in triggering a direct or 
indirect damage of the endoplasmic reticulum, since this is the main source of DAMPs 
essential for the induction of an antitumor immunological memory. 
 
8.4 Immunogenic cell death inductors 
 
In recent years, several ICD inductors have been discovered, including; conventional 
chemotherapeutics, targeted antitumor agents and other biological and physicochemical 
therapies. Unfortunately, it is clear that there is no general structure-function relationship 
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capable of grouping all the existing ICD inductors and predicting new ones, which creates a 
great problem for the discovery of new ICD-inducing therapies. Nevertheless, the most 
peculiar characteristic of ICD inductors observed, is their capacity to induce ER stress (Garg 
et al. 2015).  
 
These observations allowed the classification of ICD inductors, based on the form of ER 
stress induction for cell death and danger signaling. Based on this classification (Figure 5), 
ICD type I inductors are defined as anticancer agents that doesn't act on proteins from the ER 
in the induction of cell death but promote collateral stress of ER for signaling of danger, 
operating in multiple targets. While the ICD inductors Type II are anticancer agents that 
target the ER both for the induction of cell death and for danger signaling. This clearly shows 
that the ICD inductor type I / II concept can be used for the discovery of new ICD inductors 
based on their preferred orientation to the ER (Garg et al. 2015; Kepp et al. 2011).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Activity of immunogenic cell death inductors type I and II. Type I ICD inductors induce 
cell death through targets unrelated to ER and danger signaling through ER stress. On the other hand, 
type II ICD inductors selectively target ER to induce both cell death and danger signaling. Adapted 
from (Garg et al. 2015). 
 
From this point of view, the activation of the membrane receptor CD47 (which will be 
described below) by agonist peptides such as PKHB1, could be an interesting therapeutic 
strategy for the generation of ICD, since it has been observed to induce regulated cell death 
in chronic lymphocytic leukemia (CLL) cells inducing ER morphological changes  and CRT 
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exposure, additionally, it promotes the elimination of tumor cells more efficiently in 
immunocompetent than in immunodeficient mice (Martinez -Torres et al. 2015, Uscanga-
Palomeque et al. 2018, unpublished observations). These are some of the main reasons for 
which the activation of CD47 is a promising strategy for the induction of ICD and a potential 
treatment in cancer therapy. 
 
9. CD47 
 
CD47 is a transmembrane protein, member of the immunoglobulin superfamily, that is 
ubiquitously expressed. It was first identified as a tumor antigen in human ovarian cancer in 
the 1980s. Since then, it has been found to be expressed in different types of human tumor 
cells, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute 
lymphoblastic leukemia (ALL), Hodgkin's lymphoma (LH), bladder cancer, among other 
solid tumors (Chao, Weissman, and Majeti 2012).  
CD47 participates in diverse physiological processes, including migration, adhesion and 
cellular proliferation, among others, by its interaction with proteins like integrins, and 
thrombospondin-1. In addition, the functions of CD47 as an inhibitor of phagocytosis through 
its interaction with the signaling regulatory protein alpha (SIRPα) expressed in phagocytes, 
leads to the activation of a tyrosine phosphatase and the inhibition of myosin accumulation 
in the place of the phagocytic synapse (Chao, Weissman, and Majeti 2012). Thus, CD47 
serves as a "don't eat me" signal that helps at the recognition of the own. The main ligands 
of CD47, TSP-1 and SIRPα, are described in detail below. 
 
9.1 CD47 structure and interactions 
 
CD47 consists of an N-terminal domain of extracellular IgV type (Figure 6), followed by a 
presenilin domain that contains five segments that cross the membrane and that end in a 
variable cytoplasmic sequence (Chao, Weissman, and Majeti 2012).  
It has been shown that the IgV domain of CD47 interacts with different ligands and counter-
ligands present in the extracellular matrix or anchored to the plasma membrane. The main 
ligand of CD47 is TSP-1, a homotrimeric glycoprotein, its C-terminal domain mediates 
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CD47 binding (Isenberg et al. 2009). It has been observed that the interaction of TSP-1-CD47 
is also carried out in different species such as murine, bovine, porcine and rats, which 
indicates that this interaction is not specie-specific within mammals. The family of SIRPa, 
known as CD47 counter-receptors, is formed by three members: SIRPα binds with greater 
affinity to CD47, SIRPγ with lower affinity and SIRPb does not bind to CD47(Soto-Pantoja, 
Kaur, and Roberts 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Structure of CD47. The figure shows the extracellular IgV domain, with its 5 glycosylation 
sites (in pink), followed by the 5 transmembrane segments (MMS) (in purple), disulfide bonds (s-s in 
orange) and finally the carboxyl terminal cytoplasmic domain with its 4 possible alternative splicings, 
where the isoform 4 is the complete molecule. 
 
9.2  SIRP-α 
 
SIRPα (also known as SHPS-1, BIT, CD172a or p84) belongs to the family of membrane 
proteins involved in the regulation of leukocyte function and is a counter-receptor of CD47 
whose interaction has been shown to mediate cell adhesion. SIRPα is expressed in myeloid 
cells, including macrophages, granulocytes, myeloid dendritic cells, mast cells and their 
precursors, including hematopoietic stem cells (Subramanian, Boder, and Discher 2007). 
SIRPα has three immunoglobulin-like domains in its extracellular region and two 
immunoreceptor tyrosine-based inhibition motifs (ITIM) in its cytoplasmic region (Figure 7) 
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9.2.1 CD47 and SIRPα regulate phagocytosis 
 
APCs express receptors that control their activity, including phagocytosis, as in the case of 
SIRPα, which recognizes CD47 on the surface of the cell as a "don't eat me" signal (Navarro-
Alvarez and Yang 2011). This signal involves the activation of SIRPα-ITIMs and the 
recruitment of the phosphatases SHP-1 and -2, resulting in the inhibition of phagocytosis. In 
addition, this interaction allows macrophages to discern between a viable and an apoptotic 
cell (Martínez-Torres, 2013).  
 
 
 
 
 
 
 
 
 
Figure 7. Interactions of SIRPs with CD47. The forms of SIRP have three Ig-like domains (blue 
ovals), of which only the D1 domain of SIRPα and SIRPγ interact with the Ig domain (green oval) of 
CD47, inducing signals of activation (green arrow). SIRPβ its activation only in the presence of the 
adapter protein Dap12 but doesn't bind to CD47. Obtained from (Barclay 2009). 
 
9.3 Thrombospondin-1 
 
Thrombospondin (TSP) belongs to a family of five multifunctional proteins that can be 
divided into two subgroups: first, TSP-1 and TSP-2, homotrimers with a region of 
procollagen type and repetitive regions, and a second group consisting of TSP-3, TSP-4 and 
TSP-5, which conform homopentamers (Martínez-Torres, 2013).  
TSP-1 is a protein that is expressed mainly on the cell surface, transiently in the extracellular 
matrix in a soluble manner. It modulates cellular functions in a specific way by involving 
cell surface receptors and other components of the extracellular matrix. In adults, the TSP-1 
expression is limited to tissue remodeling sites where it resides in the extracellular space and 
determines the phenotype, structure and composition of the extracellular matrix. TSP-1 
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promotes the migration of vascular smooth muscle cells but suppresses the chemotaxis and 
motility of endothelial cells with the same potency (Mirochnik, Kwiatek, and Volpert 2008). 
The subfamily TSP-1 and TSP-2 present anti-angiogenic activities and have been shown to 
be capable of blocking tumor growth (Isenberg et al. 2009).  
In addition, TSP-1 is the main soluble ligand of CD47, that after its interaction transduces 
signals that alter cellular calcium and cyclic nucleotides signaling, integrins and growth 
factors, controls cell fate, its viability and resistance to stress (Roberts et al. 2012).  
 
 
  
 
 
 
 
 
 
 
 
Figure 8. Thrombospondin-1 (TSP-1). The figure shows that TSP1 is composed of a globular N-
terminal heparin binding domain (HBD), three chains that contain repeats of type properdin (Type 
1), epidermal growth factor like repeats (EGF, Type 2), and calcium binding (Type 3), joined by 
disulfide bonds, and another globular region in its C-terminal domain (CBD) (Gene ID: 7057), which 
is the one that interacts with CD47. Adapted from Martínez-Torres, 2013. 
 
 
As shown in Fig 8, the VVM motif in the carboxyl terminal domain of TSP-1 that binds to 
CD47 is conserved among the five families, suggesting that the binding to CD47 could be a 
universal characteristic of these families (Isenberg et al. 2009).  
The interaction of CD47/TSP-1 is involved in different biological processes. This interaction 
mediates the inhibitory signal of nitric oxide (NO), having an impact on the cardiovascular 
system, since it decreases the amount of adhesion molecules in platelets, and alters the 
calcium levels in the vascular smooth muscle cells, among other mechanisms. In addition, 
vasodilation and chemotaxis are controlled when TSP-1 inhibits the enzyme that censes and 
activates NO production, soluble guanylyl cyclase (sCG) in platelets and endothelial cells 
(Isenberg et al. 2006). Similarly, CD47 / TSP-1 plays an important role in angiogenesis, since 
it has been shown that peptides derived from TSP-1 inhibit angiogenesis induced by 
fibroblast growth factor 2 (FGF-2) in vitro and in vivo (Kanda et al. 1999). 
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9.4 CD47 as a therapeutic target in cancer 
 
According to the diverse biological functions in which CD47 is involved, on the one hand, it 
exerts the "don't eat me" signal that can be exploited by neoplastic cells and contribute to 
their survival and progression. On the other hand, it can inhibit angiogenesis by interacting 
with TSP-1 and induce cell death in chronic lymphocytic leukemia (Mateo et al. 1999) and 
breast cancer cells (Manna and Frazier 2004). The understanding of CD47, its ligands and 
signaling pathways, is fundamental to understanding its role as a therapeutic target. 
 
9.5  Induction of RCD in cancer cells 
 
It has been observed for several years that CD47 induces RCD in different cancer cell types. 
Monoclonal antibodies (mAbs) such as coated B6H12, soluble TSP-1, and peptides such a 
4N1K have been used against CD47 to induce RCD in CLL cells (Mateo et al. 1999). 
Subsequently, many researchers continued to evaluate the induction of RCD in other cell 
types, using soluble anti-CD47 mAbs in multiple ALL (CCRF-CEM) (Uno et al. 2007), 
breast cancer (MCF-7) (Manna and Frazier 2004) and AML cell lines (NB4-LR1) (Saumet 
et al. 2005), among others. Furthermore, TSP-1, or agonist peptides such a 4N1 and 4N1K 
induced RCD in leukemic and breast cancer cells (Manna and Frazier 2004). In all these 
cases, the RCD induced by CD47 retains the following characteristics: a rapid cell death, 
caspase-independent, mitochondrial membrane depolarization without release of 
proapoptotic proteins, reactive oxygen species production, phosphatidylserine exposure, 
plasma membrane permeabilization, without DNA fragmentation or chromatin condensation 
(Martínez-Torres, 2013). 
Although it was observed that peptides derived from TSP-1 activated RCD in cancer cells, 
the impossibility of their administration in a soluble manner limited the potential of their 
therapeutic use, for this reason most of the CD47 research of recent years reports the 
induction of RCD with mAbs through different mechanisms. Thus it was until 2015 when 
the CD47 agonists recovered importance when the first serum stable  agonist peptide of CD47 
was synthetized, called PKHB1, which shares the same amino acid sequence of 4N1K 
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(described above), but the natural C- and N-terminal lysines, L-amino acids were replaced 
by their equivalents D. PKHB1 was created with the intention of optimizing the poor 
solubility and serum stability of the peptides 4N1 and 4N1K, which until 2015 were the only 
CD47 agonist peptides that had been described (A.-C. Martinez-Torres et al. 2015). 
Therefore, it was demonstrated that the activation of CD47 by PKHB1 selectively induces 
calcium-regulated cell death in CLL cells from refractory patients, through ER changes, 
which leads to calcium ion overload (Ca2+) in the cytosol, damaging  lethally the 
mitochondria and inducing the proteases activation (serpases) (A.-C. Martinez-Torres et al. 
2015).  
On the other hand, the growth of CLL cell tumors (human cells) in xenotransplanted NSG 
(immunodeficient) mice was significantly reduced when treated with PKHB1 (A.-C. 
Martinez-Torres et al. 2015). In conjunction with such findings, Dènefle et al. demonstrated 
that PKHB1 is also able to induce cell death of at least lung, colon and breast cancer cell 
lines, without damaging healthy B and T cells (Denèfle et al. 2016a). In addition, recent 
results show that PKHB1 selectively kills different types of leukemia cell lines (Jurkat, CEM, 
HL-60 and K562) and a murine T-cell lymphoblastic cell line (L5178Y-R), but not primary 
cultures of non-human cancerous or murine cells (Gomez-Morales, 2017, Uscanga-
Palomeque 2018, thesis works). Cell death in different types of leukemia apparently occurs 
through a mechanism similar to that of CLL, since it depends on the influx of calcium 
(Gomez-Morales, 2017, Calvillo Rodríguez 2017, Uscanga-Palomeque 2018). 
 
9.6 Possible implications of CD47 agonist peptides in the induction of immunogenic cell 
death 
 
It is clear that the efficacy of current treatments against cancer, such as different 
chemotherapies and radiotherapies, is fundamentally based on their ability to awaken innate 
and adaptive immune responses, which depend on the immunogenicity and the adjuvant 
capacity of the tumor (Lorenzo Galluzzi et al. 2017). An interesting feature observed in CLL 
cells is that PKHB1 caused exposure of CRT to the cell surface (A.-C. Martinez-Torres et al. 
2015), an ER chaperone protein that is exposed to the cell membrane as a "eat me" signal 
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after ER stress, and which is deeply involved with the immunogenicity of cell death and 
favors the activation of immunological memory (Obeid et al. 2007).  
In addition, CD47 plays critical roles in the immune system, regulates inflammatory 
responses (Gutierrez, Lopez-Dee, and Pidcock 2011; Sarfati et al. 2008), by mediating the 
migration of leukocytes to sites of infection (Martinelli et al. 2013) or the resolution of 
inflammation by the elimination of macrophages (Calippe et al. 2017). In addition, recent 
findings show that chronic ER stress caused by the unfolded protein response (UPR) 
modulates antitumor immunity in cancer and regulates the expression of calreticulin and 
CD47 (Cook and Soto-Pantoja 2017). Finally, in our laboratory, we used PKHB1 to study its 
effects on an immunocompetent murine model with a syngeneic tumor of L5178Y-R cells, 
and we found that treatment with PKHB1 not only reduces the tumor burden in 
immunocompetent mice, but induces complete regression in most cases (Uscanga‐
Palomeque et al. 2018a), suggesting that the immune system could play a role in the 
antitumor activity of the CD47 agonist peptides. So collectively, the available data 
highlighted the potential of CD47 agonist peptides to induce non-apoptotic immunogenic cell 
death of cancer cells, which was tested in this thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  24 
10. JUSTIFICATION 
 
Cancer is one of the most important public health problems worldwide. Despite the efforts 
to treat it, innate and acquired treatment-resistance of cancer cells to current therapies remain 
one of the principal problems to solve in clinical care. Immunogenic cell death (ICD) recently 
has been recognized as a critical determinant for the efficiency of cancer therapies. Due to 
this, the current treatments seek to induce ICD in cancer cells through conventional 
chemotherapeutics, targeted antitumor agents, and other biological and physicochemical 
therapies. Unfortunately, most treatments are highly nonspecific and cause serious side 
effects that limit their use.  
From this perspective, the activation of CD47 is a promising approach in cancer therapy, 
since its activation through TSP-1 or mimetic agonist peptides, such as PKHB1, induces 
selective regulated cell death (RCD) of cancer cells. CD47-RCD is characterized by 
endoplasmic reticulum alterations and CRT exposure, one of the main DAMPs involved in 
ICD. 
Therefore, this study was conceived to expand the knowledge of the immunogenicity of this 
type of cell death and its effect on the establishment of an antitumor immune response. This 
will might extend its potential application to other types of cancer, and to evidence its 
possible advantages over the current ICD inducers. 
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11. HYPOTHESIS 
 
 
 
CD47 activation induces immunogenic cell death in cancer cells. 
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12. OBJECTIVES 
 
General Objective 
To evaluate the immunogenic cell death induced by PKHB1 in cancer cells  
 
Specific Objectives 
• To evaluate the cell death induced by PKHB1 in tumor cells. 
• To analyze the exposure or release of DAMPs from tumor cells after treatment with 
PKHB1. 
• To assess the anti-tumor immune responses induced by dead tumor cells treated with 
PKHB1. 
• To evaluate the anti-tumor effect of prophylactic and therapeutic vaccinations with 
dead cancer cells treated with PKHB1 on syngeneic mice bearing cancer cells. 
• To analyze the long-term antitumor memory induced by therapeutic vaccinations with 
dead cancer cells treated with PKHB1 on syngeneic mice bearing cancer cells. 
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13. MATERIALS AND METHODS 
 
13.1 Cell culture 
L5178Y-R (ATCC CRL-1722, murine lymphoblastic T-cell line), MDA-MB-231 and MCF-
7 (ATCC HTB-26 and ATCC HTB-22, human breast cancer cells), and 4T1 (ATCC CRL-
2539, murine breast cancer cell line) were obtained from the ATCC. Cells were maintained 
in RPMI-1640 (lymphoid cells) or DMEM-F12 (breast cancer cells) medium supplemented 
with 10% FBS, 2 mmol/L l-glutamine, 100 U/mL penicillin-streptomycin (GIBCO by Life 
Technologies, Grand Island, NY, USA), and incubated at 37°C in a controlled humidified 
atmosphere with 5% CO2. Cell count was carried out using Trypan blue (0.4% Sigma-
Aldrich), a Neubauer chamber and an optic microscope (Zeiss Primo Star) as proposed by 
the ATCC’s standard protocols.  
13.2 Cell death analysis  
1X106 cells/mL were seeded and left untreated or treated for 2 h with PKHB1 (as indicated, 
with 100, 200 and 300 µM) to obtain the cytotoxic concentration that killed 50% of the cells 
(CC50). Then, annexin-V-allophycocyanin (Ann-V-APC 0.1μg/ml; BD Pharmingen, San 
Jose CA, USA), and propidium iodide (PI, 0.5μg/ml Sigma-Aldrich) were used to assess 
phosphatidylserine exposure, cell death, and cell viability quantification, respectively, in a 
BD AccuryC6 flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) (total population 
10,000 cells). Data was analyzed using FlowJo software (LLC, Ashland, OR, USA).  
13.3 Calreticulin exposure  
1x106 cells were plated, and then left untreated (control) or treated with PKHB1(CC50), and 
incubated for 2 h (for L5178Y-R cells, poly-l-lysine was added to sterile coverslips placed 
inside a six-well plate for 24 h, then washed with PBS and 1x106 cells/mL were seeded). 
Then, the cells were washed with PBS and stained with Calreticulin-PE antibody (2μg/ml) 
and Hoechst 33342 (0.5μg/ml) (Thermo Scientific Pierce, Rockford, IL, USA), incubated for 
1h in FACS buffer, and assessed by confocal microscopy.  
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13.4 Western blot  
In a serum-free culture medium, 1x106 cells/mL were seeded and treated with PKHB1 (CC50 
for each cell line) or left alone (control) for 2 h. Supernatants were recovered and the cells 
were lysed with lysis buffer (20 mmol/L Tris pH 6.8, 2 mmol/L EDTA, 300 mmol/L NaCl 
and SDS 2%) at 98ºC for 30 minutes. Protein concentration was measured using the DC 
Protein Assay kit (Bio-Rad, Hercules, CA, USA) and 50 μg protein was loaded into SDS-
PAGE gels. After blotting, nitrocellulose filters were probed with primary antibodies HSP90 
(F-8: SC-13119) and Calreticulin (F-4: sc373863). Anti-mouse or anti-rabbit-HRP served as 
secondary antibodies (Santa Cruz Biotechnology). Visualization was carried out with ECL 
substrate system (Thermo Scientific, Waltham, MA, USA).  
13.5 ATP release assay  
1x106 cells/mL were treated with PKHB1 (CC50 for each cell line) for 2 h. Supernatants were 
used to assess extracellular ATP by a luciferase assay (ENLITEN kit, Promega, Madison, 
WI, USA) following the manufacturer’s instructions. Bioluminescence was assessed in a 
microplate reader (Synergy HT, Software Gen5; BioTek, Winooski, VT, USA) at 560 nm.  
13.6 High-mobility group box 1 release assay  
Supernatants of untreated and treated cells (PKHB1 CC50 for each cell line and CC100 only 
for L5178Y-R) cells (1x106 cells/mL) were used to measure extracellular HMGB1 using the 
HMGB1 ELISA kit for MDA-MB, MCF-7 or L5178Y-R and 4T1 cells (BioAssay ELISA 
kit human or mouse, respectively; US Biological Life Science Salem, MA, USA), following 
the manufacturer’s instructions. Absorbance was assessed at 450 nm.  
13.7 T-cells and dendritic cells (DCs) 
 
This study was approved by the Animal Ethical Committee (CEIBA), of the School of 
Biological Sciences Number: CEIBA-2018-003. All experiments were conducted according 
to Mexican regulation NOM-062-ZOO-1999. 
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The blood from sacrificed BALB/c mice was obtained by cardiac puncture. Peripheral blood 
mononuclear cells (PBMCs) isolation was performed by density gradient centrifugation 
using Ficoll-Hypaque-1119 (Sigma-Aldrich, St Louis, MO, USA). Murine CD3+ cells were 
isolated from total PBMCs by positive selection using magnetic-activated cell sorting 
(MACS) microbead technology with anti-CD3e-biotin and anti-biotin microbeads (Miltenyi 
Biotech; >98% purity and >98% viability), as stated by manufacturer’s instructions. 
To obtain bone marrow-derived dendritic cells (DCs), after sacrifice, mice bone marrow was 
removed from femur and tibia of female BALB/c mice by flushing into RPMI-1640. Eluted 
cells were cultured for 5 days with 20 ng/mL of IL-4 and GM-CSF (R&D Systems, 
Minneapolis, MN, USA) until approximately 70% of the cells were CD11c+. 
 
13.8 DCs markers 
 
DCs (1x106 cells/mL) were stained in 100µL of FACS buffer with the indicated antibodies 
at RT for 30 minutes and then washed twice with PBS. The cell surface markers were 
evaluated by flow cytometry with the fluorescent label-conjugated antibodies, antiCD11c-
Alexa-fluor 488 (R&D Systems), antiCD80-FITC and antiCD86-APC, from BD Biosciences 
(San Jose, CA, USA). 
 
13.9 Co-cultures  
 
DCs-PKHB1 tumor cell lysate: DCs were resuspended in fresh medium at a concentration of 
1x106 cells/mL. DCs were left untreated (control) or PKHB1-Treated tumor cells were added 
at a concentration of 3×106 cells/mL (L5178Y-R or 4T1 cells) to give a range of 1:3 DCs to 
PKHB1-treated tumor cells ratios. Co-culture was left for 24 hours. Then the supernatant was 
removed, and the well was washed twice with PBS before doing the next co-culture (with the 
addition of 4T1 or L5178Y-R cells respectively). 
DCs-T-lymphocytes: Control DCs or DCs previously co-cultured with PKHB1-TCL were 
maintained in fresh medium at a concentration of 1x106 cells/mL. Then, allogeneic BALB/c 
mCD3+ cells were added to each well at 3x106 cells/mL to give a range of 1:3 DC to CD3+ 
cells ratios. Coculture was left for 96 hours. Then, the lymphocytes were collected (by 
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obtaining the supernatant), washed with PBS, and resuspended in fresh medium at a 
concentration of 5x106 cells /mL for their use in the next co-culture (T- lymphocytes with 
cancer cells). 
T-Lymphocytes-Tumoral cells cells: viable 4T1 or L5178Y-R cells were plated at a 
concentration of 1x105 cells/mL. Then, unprimed (previously co-cultured with control DCs) 
or primed (previously co-cultured with DCs-PKHB1-TCL) allogeneic BALB/c mCD3+ cells 
were added to each well at 5×105 cells/mL to give a range of 1:5 tumor to effector ratios. Co-
culture was left for 24 hours, before cytokine or calcein assessment 
 
13.10 Cytokine release assay 
 
The supernatants from the indicated cultures were collected for IL-2, IL-4, IL5, and TNFa 
assessment (BD, CBA Mouse Th1/Th2 Cytokine Kit, San Jose, CA, USA) by flow cytometry 
following manufacturer’s instructions. IFNγ was assessed using an ELISA kit (Sigma-
Aldrich) and using the Synergy HTTM (BioTek Instruments, Inc., Winooski, VT, USA) plate 
reader at 570 nm wavelength, following manufacturer’s instructions. 
 
13.11 Calcein assay  
L5178Y-R or 4T1 cells (1x106 cells/mL) were stained with (0.1mL/mL) of Calcein-AM from 
BD Biosciences (San Jose, CA) for 30 minutes, then washed twice with PBS. After this, T 
cells previously primed with DCs pulsed with PKHB1-TCL or with unpulsed DCs were 
added in a 1:5 ratio. The co-culture was incubated at 37 °C and 5% CO2 for 24 h. Finally, 
calcein positive or negative cells were assessed in a BD AccuryC6 flow cytometer (BD 
Biosciences) (total population 10,000 cells). Data was then analyzed using FlowJo software.  
13.12 In vivo model 
 
Six-to-eight-week-old BALB/c female mice were maintained in controlled environmental 
conditions (25ºC and 12 h light/dark cycle) and were supplied with rodent food (LabDiet, St. 
Louis, MO, USA) and water ad libitum. 
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13.13 Prophylactic vaccinations  
L5178Y-R cells (5x106) or 4T1 cells (3x106) were treated with 350 or 400 μM PKHB1 
(CC100) respectively in serum-free medium for 2 h. Cell death was confirmed using Trypan 
blue staining and flow cytometry. Treatment was carried out as follows: PKHB1-TCL was 
inoculated s.c. in 100 μL of serum free medium into the left hind leg (day -7), seven days 
later viable (2 × 106) L5178Y-R or (5 × 105) 4T1 cells were inoculated into the right hind leg 
(day 0). Tumor volume and weight were measured three times per week using a caliper 
(Digimatic Caliper; Mitutoyo Corporation, Kawasaki, Japan) and a digital scale (AWS-600-
BLK American Weigh Scales Inc. Norcross, GA, USA). Tumor volume was determined with 
the formula: tumor volume (mm3) = 4π/3 * A * B * C where 4π / 3 is a mathematical constant, 
A= width, B= high, and C= depth. 
13.14 Therapeutic vaccinations  
Tumor was established by subcutaneous injection of 2x106 L5178Y-R or 5x105 4T1 cells in 
100 μL PBS, in the left hind. Tumor volume and mice weight were measured how was 
described above. When the tumor reached 100 mm3 the first therapeutic-vaccine of PKHB1-
tumor cell lysate (PKHB1-TCL) was applied as follows; L5178Y-R cells (5x106) or 
4T1(3x106) cells were treated in vitro with 300 or 400 μM PKHB1 for 2 h (CC100) in serum-
free RPMI medium. Cell death was confirmed as previously indicated. Treated cells were 
inoculated subcutaneously in 100 µl serum free media, in the right hind, twice a week. 
Controls were treated with 100 µl serum free media. 
13.15 Long-term memory assay  
Mice in complete remission after prophylactic or therapeutic vaccination treatments were re-
challenged with 2x106 L5178Y-R or 5x105 4T1 viable cells in 100 μL PBS into the opposite 
limb, and tumor volume was measured as described above.  
13.16 Statistical analysis  
Mice were randomly assigned to different groups for all in vivo studies. Independent 
experiments were repeated three independent times. Mann-Whitney tests and two-tailed 
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unpaired Student's t-tests were performed using GraphPad Prism Software (San Diego CA, 
USA) and presented as mean values ±SD. The p values were considered significant as 
follows: p<0.05; p<0.01 and p<0.001. 
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14 RESULTS 
 
14.1 CD47 agonist peptide, PKHB1, induces cell death in tumor cells 
The thrombospondin‐1 mimetic peptide PKHB1 has shown cytotoxicity in several neoplastic 
cell lines, mostly in hematopoietic malignances (A.-C. Martinez-Torres et al. 2015; Denèfle 
et al. 2016a) . In this thesis the objective was to evaluate its effects in a murine T-cell 
lymphoblastic tumor cell line, L5178Y-R, and in human breast cancer cell lines, MCF-7 and 
MDA-MB-231, as well as on the murine homologous, 4T1 cell line. PKHB1 induces cell 
death in a concentration‐dependent way, because the cells incubated for 2 h with increasing 
concentrations (100, 200 and 300 μM) of PKHB1 showed an increase number of Ann‐V‐
APC/PI positive L5178Y-R (Figure 9A), 4T1 (Figure 9B),  MDA-MB-231 (Figure 9C) and 
MCF-7  (Figure 9D)  cells. The cytotoxic concentration that induces approximately 50% of 
cell death (CC50) in L5178Y-R is 200 μM, in 4T1 is 300 μM, in MDA-MB-231 is 200 μM 
and in MCF-7 is 300 μM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 9. PKHB1 induces cell death in different cancer cell lines. Cell death was measured by 
Annexin-V- allophycocyanin (Annexin-V-APC) and propidium iodide (PI) staining and graphed. Dot 
plots of (A) L5178Y-R murine lymphoblastic T-cell line, (B) 4T1 murine breast cancer cells, (C) 
MDA-MB-231 and (D) MCF-7 human breast cancer cell lines, without treatment (Control) and 
treated with 100, 200 and 300 μM of PKHB1 for 2 h. Graphs represent the means (± SD) of triplicates 
of at least three independent experiments (right side for each cell line). 
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14.2 PKHB1 treatment induces calreticulin exposure 
To assess the immunogenicity of the cell death induced by the activation of CD47 by PKHB1 
in cancer cells, first the exposure of CRT was evaluated, since this protein is one of the 
principal DAMPs necessary for the correct maturation of DCs and antigen presentation on 
ICD (Obeid et al. 2007; Garg et al. 2015). Additionally, previous results using PKHB1 
displayed CRT exposure in CLL (A.-C. Martinez-Torres et al. 2015).  The results in Figure 
10 show that PKHB1 treatment is able to induce CRT exposure in all the cell lines tested.  
 
 
FIGURE 10. PKHB1 treatment induces calreticulin exposure. ECTO-CRT was observed by 
confocal microscopy 40× (Mechanical zoom 7, Olympus X70; Olympus, Tokyo, Japan) in the cells 
left untreated (Control) or treated with PKHB1, using CRT-PE staining and Hoechst 33342 (for 
nuclear staining). Results shown are representative of triplicates of three independent experiments. 
CRT-PE= Calreticulin-PhycoErythrin. 
 
 
14.3 Expression and release of HSP90 and CRT in tumor cells and supernatants 
Different ICD inductors can lead to DAMPs release by cancer cells (Krysko et al. 2012; 
Garg et al. 2015). For this reason, once confirmed that PKHB1 treatment induce CRT 
exposure in cancer cells, the presence of DAMPs was evaluated in cellular lysates and 
supernatants of untreated and PKHB1‐treated cells (CC50 for each cell line), by Western blot.  
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Figure 11A shows the decrease in the expression of HSP90 and CRT in cellular lysates of 
cells treated with PKHB1. Conversely, the increase of these DAMPs was observed in 
PKHB1‐treated cells’ supernatants compared with the untreated cells by western blot 
(Figure11). These results indicate that PKHB1 treatment prompts the release of HSP90 and 
CRT to the extracellular medium.  
 
FIGURE 11. Heat shock proteins (HSP90, HSP70) and calreticulin (CRT) expression and 
release in response to PKHB1 treatment. Western blot was carried out using cellular lysates (A) or 
supernatants (B) of L5178Y-R, 4T1, MDA-MB-231 and MCF-7 cells untreated (CTR) and treated 
with PKHB1 (CC50) for 2 h. β-actin and Ponceau red were used and loading controls. Results shown 
are representative of triplicates of at least three independent experiments.  
14.4 HMGB1 and ATP release by PKHB1 treatment in cancer cells 
Another important indicator of ICD is the release of HMGB1 and ATP by the dying cancer 
cells (Krysko et al. 2012; Garg et al. 2015). Therefore, the presence of HMGB1 and ATP in 
the supernatants of treated and untreated cancer cells was assessed by ELISA or 
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bioluminescence detection (respectively). Results show a significant release of HMGB1 and 
ATP in PKHB1-treated cells (Figure 12A and B), when compared with untreated cells. These 
results indicate that PKHB1 treatment induces the release of HMGB1 and ATP in all the 
cancer cells tested. 
Figure 12. PKHB1 treatment induces high-mobility group box1 (HMGB1) and ATP release. 
Cells were treated with PKHB1 (CC50 or CC100) for 2 h, then 100 μL supernatant of each sample was 
taken to measure HMGB1 release by ELISA (A) or ATP release through bioluminescence detection 
(B). Graphs shown are means (± SD) of triplicates of three independent experiments. NS= Not 
significant.  
14.5 PKHB1-TCL induces maturation of bone marrow-derived DCs  
As previously indicated, DAMPS release is not determinant for ICD, and ex vivo and in vivo 
analyses are necessary to confirm ICD. To assess the antitumor immune response induced 
by PKHB1, a tumor cell lysate through PKHB1 CC100 treatment was obtained (PKHB1-
TCL). Then, it was determined if the PKHB1-TCL was able to induce DCs maturation, 
through the evaluation of the expression of CD80, CD86, and the release of TNFa, indicators 
of a mature DCs phenotype (Dudek et al. 2013). Bone marrow-derived murine DCs were 
left untreated (Control) or pulsed for 24 h with the previously obtained PKHB1-TCL. After 
co-culture with PKHB1-TCL, DCs show a significant increase in the expression of co-
stimulatory molecules CD80 and CD86 passing from 50% to 78% and 83%, respectively in 
L5178Y-R-PKHB1-TCL, and from 50% to 60% and 90%, respectively in 4T1-PKHB1-
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TCL, while maintaining the expression of the DCs marker CD11c in both cases (Figure 13 
A, B). Furthermore, only DCs pulsed with PKHB1-TCL show a significant increase in TNFa 
release in comparison with unstimulated DCs (Figure 13 C, D). These results show that 
PKHB1-induced cell death is able to promote DCs maturation. 
 
 
 
Figure 13. PKHB1-Tumor cell lysate induces the maturation of bone marrow-derived dendritic 
cells. (A) Bone marrow-derived murine DCs were left only with medium (Control) or pulsed during 
24 h with a PKHB1-TCL. DCs were then stained to assess cell surface markers (CD11c, CD80, or 
CD86) by FACS, and representative histograms are shown.  (B) The means obtained by FACS were 
graphed for each TCL. (C) DCs were treated as in A and the supernatants were collected to quantify 
TNFa release, by FACS. Graphs represent the means (± SD) of triplicates of at least three independent 
experiments. 
 
14.6 PKHB1-TCL induces anti-tumor T cell responses  
Once determined that PKHB1-TCL was able to induce DCs maturation, it was assessed if 
the pulsed DCs (DCs-PKHB1-TCL) were able to prime T cells. First, CD3+ cells were co-
cultured for four days with pulsed or unpulsed DCs and the release of TNFa, IFNg, IL-5, 
IL-4, and IL-2 was assessed. Table 1 shows that co-culture of pulsed DCs with primary T 
lymphocytes induces the release of TNFa, IFNg, and IL-2, while IL-5 and IL-4 release were 
not detected.  
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Table 3. TNFa, IFNγ, IL-5, IL-4, and IL-2 cytokine release in co-cultures of T lymphocytes with 
control or pulsed DCs. Bone marrow-derived murine DCs were left with medium alone (DCs-
Control) or pulsed (DCs-PKHB1-TCL) during 24h with a PKHB1-TCL. Then, DCs were co-cultured 
during 4 days with T-lymphocytes, and the supernatants were collected to quantify TNFa, IFNγ, IL-
5, IL-4, and IL-2 release, by FACS. **p<0.01; ***p<0.001. 
 
Next, primed (co-cultured with pulsed DCs-PKHB1-TCL) or unprimed (co-cultured with 
unpulsed DCs) T-lymphocytes were collected and co-cultured during 24h with L5178Y-R 
or 4T1 cells (previously stained with calcein-AM). Then, supernatants were obtained and 
IFNg, IL-4, and IL-2 cytokine release was assessed. A significant increase of IFN-γ release 
was observed in the supernatants of primed T-lymphocytes when being co-cultured with 
L5178Y-R cells (Figure 14 A) or 4T1 cells (Figure 14 B), similarly, a significant increase of 
IL-2 release was observed (Figure 14 C, D) while no difference was observed in IL-4 release 
(Figure 14 C,D).  
 
 
TNFa 
(pg/mL) 
IFNg 
(pg/mL) 
IL-5 
(pg/mL) 
IL-4 
(pg/mL) 
IL-2 
(pg/mL) 
DCs-Control  
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38.9 
± 14 
0  
± 0 
0  
± 0 
0  
± 0 
0.2  
± 0.2 
DCs-PKHB1-TCL 
(L5178Y-R)  
+ T-lymphocytes 
479.6** 
± 156 
974.33*** 
± 115 
0 
± 0 
0 
± 0 
3.5*** 
± 0.7 
DCs-PKHB1-TCL 
(4T1)  
+ T-lymphocytes 
335.17*** 
± 33.64 
698.95 ** 
± 322.54 
0 
± 0 
0 
± 0 
1.83* 
± 1.4 
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Figure 14.  IFN-γ, IL-4 and IL-2 secretion by unprimed or primed T cells co-cultured with 
murine tumor cells. L5178Y-R or 4T1 cells were co-cultured with unprimed T lymphocytes 
(previously co-cultured with unstimulated DCs-Control) or primed T-lymphocytes (previously co-
cultured with pulsed DCs-PKHB1-TCL) in a 1:5 tumor to effector ratio, for 24 h and the supernatants 
were collected and assayed for  IFN-γ release by ELISA (A,B) and  IL-4 and IL-2 release by FACS 
(B,C). 
Once we observed that PKHB1-TCL induced IFNg and IL-2 release, suggesting Th1 
responses (Viallard et al. 1999), we assessed antitumor cell cytotoxicity. For this purpose, 
we evaluated the decrease in calcein stained L5178Y-R or 4T1 cells after co-culture with 
primed or unprimed T-lymphocytes. Results show that only T-lymphocytes co-cultured with 
pulsed DCs-PKHB1-TCL induce a significant decrease in calcein stained L5178Y-R (Figure 
15 A) and 4T1 (Figure 15 B) cells, in comparison with the L5178Y-R and 4T1 cells 
cocultured with unprimed T lymphocytes (Figure 15 A, B respectively). This confirms the 
correct antigen presentation by DCs-PKHB1-TCL and the T cell cytotoxicity against 
L5178Y-R and 4T1 cancer cells. 
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Figure 15. Primed T cells’ cytotoxicity in murine cancer cells. (A) L5178Y-R or (B) 4T1 cells 
were stained with calcein-AM and co-cultured with unprimed T lymphocytes (previously co-cultured 
with unstimulated DCs-Control) or primed T-lymphocytes (previously co-cultured with pulsed DCs-
PKHB1-TCL) in a 1:5 tumor to effector ratio for 24h. The percentage of L5178Y-R or 4T1 calcein 
negative cells was assessed by FACS; representative histograms are shown. Graphs at the right 
represent the means (± SD) of triplicates of at least three independent experiments. 
14.7 The prophylactic vaccine with PKHB1‐treated cells prevented the tumor 
establishment of L5178Y‐R and 4T1 cells 
Considering that PKHB1 treatment induces DAMPs release and an antitumor immune 
response ex vivo, the next step was to carry out a prophylactic vaccination, to confirm ICD. 
The vaccine is based in the use of PKHB1-TCL of L5178YR or 4T1 cells. Two groups of 
mice were used as follows for every tumor (L5178Y-R or 4T1) model: (I) control group 
without vaccine; (II) vaccine group, with 5x106 of L5178Y-R or 3x106 4T1 PKHB1‐treated 
cells. Results showed that vaccination containing PKHB1‐treated cells prevented the 
establishment of Lymphoma (L5178Y-R) and Breast cancer (4T1) tumor models (Figure 16 
A, B). In the control group of L5178Y-R, six out of six mice (100%) developed tumor after 
inoculation with viable cells, whereas none of the mice (0%) in the 5M vaccine group 
developed the tumor (Figure 16A). In the control group of 4T1, eight out of eight mice 
(100%) developed tumor after inoculation with viable cells, whereas two of ten mice (20%) 
in the 3M vaccine group developed the tumor (Figure 16 B). The 60‐day survival rates of 
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mice in each group were consistent with tumor growth, being 100% in the 5M vaccine group 
for lymphoma model (L5178Y-R) and 80% in the breast cancer model (4T1) (Figure 16 C, 
D). 
 
 
Figure 16. PKHB1-TCL prevents the tumor establishment through a single prophylactic 
vaccination. (A) Graph indicates tumor growth in unvaccinated mice of L5178Y-R (Control; n = 6) 
or vaccinated with 5x106 (PKHB1-TCL-L5178Y-R, n= 6) CC100 PKHB1-treated L5178Y-R cells and 
re-challenged with 2x106 L5178Y-R cells. Each line represents the mean of the tumor volume per 
group. (B) Graph indicates tumor growth in unvaccinated mice of 4T1 (C, Control; n = 8) or 
vaccinated with 3X106 (PKHB1-TCL-4T1, n=10) CC100 PKHB1-treated 4T1 cells and re-challenged 
with 5X105 4T1 cells. Each line represents the mean of the tumor volume per group. (C, D) Kaplan 
Meier survival graph of mice treated as in A and B over time 
 
14.8 PKHB1-TCL induces tumor regression 
After the ex-vivo and in vivo results, then it was evaluated if the PKHB1-TCL was able to 
diminish tumor growth and improve overall survival in syngeneic mice transplanted with 
L5178Y-R or 4T1 cells. First, viable cells were inoculated in BALB/c mice, and when the 
tumor reached 100 mm3, a mice control-group was left without treatment, and a second group 
was treated with PKHB1-TCL two times per week for a total of four injections (Figure 17 
A). Tumor growth measurements show that PKHB1-TCL-treated mice had a significantly 
diminished tumor growth after day 10 (7 days after the first treatment), which continued to 
decrease until no tumor was detected by day 30, for both lymphoma and breast cancer models 
(Figure 17 B, C). Tumor growth diminution was reflected in overall mice survival, as 
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L5178Y-R-PKHB1-TCL-treated mice presented an 80% of survival over time, while all 
control mice perished by day 11 (Figure 17 D). In the breast cancer model as 4T1-PKHB1-
TCL-treated mice presented an 80% of survival over time, while all control mice perished 
by day 24 (Figure 17 E).  
When observing that PKHB1-TCL induces tumor remission in two completely different 
tumor models (lymphoma and breast cancer), the strength of the immunogenicity of death 
induced by CD47 activation is evidenced. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. PKHB1-TCL treatment induces tumor regression, increasing mice’s survival over 
time. (A) Schema of PKHB1-TCL (5 × 106 or 3x106 PKHB1-treated L5178Y-R or 4T1 cells 
respectively) treatment started when tumor reached 100 mm3, then PKHB1-TCL was administrated 
every 3 days for two weeks (for a total of four injections). (A) Graph indicates tumor growth in 
unvaccinated mice of L5178Y-R (Control; n = 7) or vaccinated with 5x106 (PKHB1-TCL-L5178Y-
R, n= 9) CC100 PKHB1-treated L5178Y-R cells. Each line represents the mean of the tumor volume 
per group. (B) Graph indicates tumor growth in unvaccinated mice of 4T1 (C, Control; n = 9) or 
vaccinated with 3X106 (PKHB1-TCL-4T1, n=9) CC100 PKHB1-treated 4T1 cells. Each line 
represents the mean of the tumor volume per group. (C, D) Kaplan Meier survival graph of mice 
treated as in A and B over time.  
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14.9 PKHB1-TCL therapeutic vaccination induces long-term antitumor memory 
To assess the immunological memory against tumor antigens induced by PKHB1-TCL-
treatment, mice in complete remission (tumor free >60 days) were re-challenged with living 
L5178YR or 4T1 cells. Compared to naïve mice (Control), in which a primary L5178YR 
cells challenge resulted in a 0% of survival and all control mice perished by day 22, those 
that were in remission were completely resistant to a re-challenge of L5178YR cells resulted 
in a 100% of survival (Figure 18 A). In the breast cancer model, control mice after primary 
4T1 cells challenge resulted in a 0% of survival in which all control mice perished by day 
24, and those that were in remission were completely resistant to a re-challenge of 4T1 cells 
resulted in a 100% of survival (Figure 18 B). 
 
 
Figure 18. PKHB1-TCL therapeutic vaccination induces long-term antitumor memory. Mice in 
remission after therapeutic vaccinations were re-challenged with 3x106 L5178Y-R (A) or 5x105 4T1 
(B) viable cells. Survival is represented by the Kaplan-Meier graph. (A) Control n = 9, PKHB1-TCL 
n = 9. (B) Control n = 8, PKHB1-TCL n = 7.  
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15. DISCUSSION 
"The danger theory", proposed by Polly Matzinger (Matzinger 1994), establishes that the 
main trigger for the induction of an immune response are the "danger signals" recognized by 
the immune system cells. These signals were later called damage-associated molecular 
patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs), and it is now known 
that the absence of these signals results in immune-tolerance. One of the applications of this 
theory is in the context of antitumor therapy, especially after the description of the 
immunogenic types of cell death.  ICD is a type of cell death that is able to activate antitumor 
immune responses through the release or exposure of DAMPs (Garg et al. 2015). Currently, 
this type of cell death is a critical determinant of the efficacy of antitumor treatments, since 
its execution may lead to the elimination of chemo-resistant cells with a high recurrence rate 
(Garg et al. 2015). For this reason, current therapeutic strategies search the induction of ICD. 
In this context, our research group previously demonstrated that the activation of CD47 by 
agonist peptides derived from TSP-1 such as PKHB1 induces regulated cell death, causing 
calreticulin exposure and morphological changes of ER in CLL, two characteristics 
intimately related to ICD. Therefore, within this thesis it was explored the immunogenicity 
of cell death induced by the activation of CD47 in murine lymphoma cells L5178Y-R (T-cell 
lymphoblasts), breast cancer cells from mice, 4T1 (triple negative), and human, MDA-MB-
231 (triple negative) and MCF-7 (Luminal A). 
 
In summary, this thesis describes the immunogenicity of the cell death induced by the 
activation of CD47. Here I will discuss the five main aspects of my thesis’ results: 
 
1. Molecular characteristics of the ICD induced by the activation of CD47  
2. Effect of CD47-ICD on the immune response 
3. PKHB1-TCL from the proof of concept to therapeutic potential 
4. CD47-ICD and immunological memory 
5. CD47 activation by agonist peptides: an ideal ICD strategy? 
 
Through the following pages it will be discussed the relevance, scope and perspectives of the 
results obtained. 
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1. Molecular characteristics of the ICD induced by the activation of CD47 
 
The RCD induced by CD47-agonist peptides has been reported in different types of cancer, 
including lung, colon, breast and leukemia cancers (Manna and Frazier 2004; A.-C. 
Martinez-Torres et al. 2015; Denèfle et al. 2016a). In all cases, peptides such as 4N1K and 
PKHB1 induce a dose-dependent cell death (Manna and Frazier 2004; A.-C. Martinez-Torres 
et al. 2015; Denèfle et al. 2016a). As previously reported, here it was found that PKHB1 
induces a dose-dependent cell death, because as the concentration of PKHB1 increases (100, 
200 and 300uM) the percentage of cell death increases. In addition, it was observed that the 
mean cytotoxic concentration (CC50) of PKHB1 was: 200µM for L5178Y-R and MDA-MB-
231 cells and 300µM for 4T1 and MCF-7 cells. 
 
The mechanism of cell death induced by CD47-agonist peptides, is characterized by being 
calcium-dependent and dependent of the phosphorylation of PLCg1 in CLL cells (A.-C. 
Martinez-Torres et al. 2015). Thus, it is logical to think that a higher expression of proteins 
involved in calcium signaling can confer to the cancer cells a greater susceptibility to this 
type of RCD. In this sense, the most sensitive cells to CD47-RCD were the L5178Y-R and 
MDA-MB-231 cells. It is important to note that the L5178Y-R cells are tumor T 
lymphoblasts, which highly express PLCg1 (Irvin et al. 2002), while MDA-MB-231 cells 
have been reported to overexpress proteins involved in the regulation of calcium, such as 
PLCg1 and ORAI1, when compared to MCF-7 (McAndrew et al. 2011; Abalsamo et al. 
2012). These molecular characteristics may confer an increased susceptibility to CD47-RCD 
in L5178Y-R and MDA-MB-231 cells.  
 
On the other hand, the 4T1 cell line is a murine model of breast cancer that has been widely 
used in research due to its tumorigenic and invasive capacity, and which has a great similarity 
with the MDA-MB-231 cell line, sharing characteristics such as lack of estrogen, 
progesterone, and growth factor receptors, in addition to resembling a late stage of breast 
cancer in vivo (Pulaski and Ostrand-Rosenberg 2001). Despite the similarities found between 
these two cell lines, I observed a lower susceptibility to CD47-RCD in 4T1 cells, indicating 
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that these could have different molecular characteristics than MDA-MB-231 cells that have 
not been reported until today. 
 
The general, resistance of cancer cells against immunosurveillance and antitumor immunity 
is achieved by mechanisms including: low immunogenicity, the ability to induce 
immunosuppression, and resistance to death by immune cells (Dunn et al. 2002; Kroemer et 
al. 2013; Garg et al. 2015). The low immunogenicity of tumor cells is the main obstacle in 
the reactivation of the antitumor immune response, therefore it was proposed that a way to 
reactivate potent antitumor immune responses is accentuating the immunogenicity of cancer 
cells (Casares et al. 2005) by the emission of danger signals or damage associated molecular 
patterns (DAMPs) (Kepp et al. 2014). Recently, it was demonstrated that the induction of a 
cancer cell death pathway called "immunogenic cell death" is defined as a functionally 
distinct form of regulated cell death that facilitates the establishment of an adaptive immune 
response, thanks to the emission of DAMPs and neoantigens, increasing the immunogenicity 
of moribund cells (Kepp et al. 2014; Garg et al. 2017). 
 
Therefore, once determined that PKHB1 is cytotoxic in the cell lines proved, the 
immunogenicity of cell death was evaluated, determining the exposure or release of DAMPs 
involved with ICD, which are calreticulin (CRT) , heat shock proteins (HSP90), HMGB1, 
and ATP (Garg et al. 2015). 
 
The first DAMP to be evaluated was CRT, because it is one of the main molecules necessary 
to determine that cell death is immunogenic (Obeid et al. 2007; Bezu et al. 2015), and its 
exposure in the cell membrane has been continuously reported as one of the main DAMPs 
necessary for the correct maturation of DCs and antigen presentation (Obeid et al. 2007; Garg 
et al. 2015). In addition, it was previously reported that the activation of CD47 by PKHB1 
induces CRT exposure in CLL cells (A.-C. Martinez-Torres et al. 2015). Here it was 
demonstrated that PKHB1 is capable of inducing CRT exposure in L5178Y-R, 4T1, MDA-
MB-231 and MCF-7 cells. With this, it is confirmed that PKHB1 is able to induce the CRT 
exposure in other types of cancer cells, this being the first report of CRT exposure by 
treatment with PKHB1 in breast cancer cells. 
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There is a close correlation between the expression of CRT and CD47 in cancer cells. It has 
been observed that the expression of CRT is an early event in newly arising neoplasms and 
only cells that increase the expression of CD47 can avoid phagocytosis (Chao et al. 2010). 
Contrary to the "don´t eat me" signal that generates CD47, it has been observed that the 
peptide 4N1K, derived from TSP-1, when bound to CD47, is capable of promoting 
phagocytosis of the target cell, depending on the conformation of CD47 (Burger et al. 2012). 
With this, the use of CD47 as a target for the induction of cell death becomes more attractive, 
since in addition to taking advantage of its over-expression in most types of cancers reported, 
peptides such as PKHB1 could also promote the phagocytosis of cancer cells. However, there 
is a lack of evidence to determine what happens after PKHB1 activates CD47 and induces 
cell death. CD47 is internalized? PKHB1 dissociates and continues to activate other CD47`s? 
does PKHB1 promotes the formation of CD47 clusters? for example. 
 
In addition to CRT exposure, different ICD inductors can promote the release of others 
DAMPs and induce the activation of a potent antitumor response (Krysko et al. 2012; Kepp 
et al. 2014). Therefore, additionally to determining the exposure of CRT, its release was also 
evaluated, as well as that of other DAMPs: HSP90, HMGB1 and ATP. 
 
These results demonstrate that PKHB1 is able to induce the release of CRT, HSP90 and ATP 
in all tumor cells assessed and only in L5178Y-R cells the release of HMGB1 was not 
detectable in the conditions it was assessed, however, recently we found that the CC100 of 
PKHB1 effectively induce the HMGB1 release (Uscanga‐Palomeque et al. 2018a). It has 
been observed that the presence of all DAMPs is not necessary for cell death to be defined 
as immunogenic (Bezu et al. 2015), additionally neither the presence of all DAMPs is 
sufficient evidence to ensure the induction of MCI. Therefore, the analysis of molecular 
determinants of ICD is not sufficient to determine that ICD is taking place. In fact, the 
analysis of DAMPs should be considered complementary to the analysis of the immune 
response ex vivo and in vivo to conclude that an agent / strategy is an ICD inductor (Garg et 
al. 2015). This is why our next step was to evaluate these parameters after cell death induction 
by PKHB1. 
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2. Effect of CD47-ICD on the immune response 
 
It is important to know the effect of the DAMPs released or exposed after the CD47-ICD 
induction in the activation of the immune response. CRT, HSP90, ATP and HMGB1 are 
recognized by a wide range of receptors among which are: CD91, purinergic receptors (P2Y2 
and P2X7), toll-like receptors (TLR2 and 4) and Scavenger receptors (SREC1 and FEEL1) 
among others, which promote the phagocytosis of cellular debris, induce the migration of 
phagocytic cells, promote the antigen presentation and induce the cytokines’ release, 
culminating in the activation of the specific antitumor immune responses (Krysko et al. 2012; 
Garg et al. 2015). 
 
Due to the importance of DAMPs in the activation of the antitumor immune response, it was 
evaluated whether the dead tumor cells treated with PKHB1 (PKHB1-TCL) promote the 
establishment of the antitumor immune response, through the maturation of dendritic cells 
and consequent activation of T lymphocytes. 
 
The phenotype of mature DCs is characterized by the expression of the CD11c differentiation 
receptor (Laursen et al. 2018), and a greater expression of CD80 and CD86 co-stimulatory 
molecules (Dudek et al. 2013). Here it was demonstrated that cell death induced by PKHB1 
in L5178Y-R (PKHB1-TCL-L5178Y-R) and 4T1 (PKHB1-TCL-4T1) cells is able to 
promote the maturation of DCs since this induced a significant increase in the expression of 
CD80 and CD86 co-stimulatory molecules, as well as the significant release of TNFa. A 
slight (non-significant) decrease in the expression of CD11c was also observed, which is a 
marker of differentiation that can be regulated downwards by dendritic cells after being 
activated by TLR agonists (Singh-Jasuja et al. 2013). 
 
The secretion of TNFa has been associated with a mature phenotype of DCs, since it acts as 
an autocrine maturation factor for DCs (Dudek et al. 2013). Several TCLs can induce their 
secretion in different degrees, from 20 pg / mL to 250 pg / mL (Chiarella et al. 2008; Chiang 
et al. 2013). In this work it was observed that the DCs pulsed with the PKHB1-TCL-L5178Y-
R induced the secretion of TNFa at a concentration of 270 pg / ml and the PKHB1-TCL-4T1 
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at a concentration of 600 pg/ml, in both cases was a greater release than most of the reports 
where they use TCL, which indicates the effective maturation of the DCs and the high 
immunogenicity of the PKHB1-TCL. 
 
On the other hand, different types of TCL can induce the DCs maturation in different degrees 
(Chiang, Coukos, and Kandalaft 2015); however, most of them use LPS (Chen et al. 2012)  
or other adjuvants such as phyto-extracts (Chang et al. 2013)  and bacterial ghosts 
(Dobrovolskienė et al. 2018)  in combination with TCL. The results obtained in this thesis 
demonstrate that cell death induced by PKHB1 is able to promote DCs maturation and TNFa 
secretion, even in the absence of other immunological stimulants. In this way, we can confirm 
that DAMPs and neo-antigens released by the treatment with PKHB1 in the cell lines used 
promote the efficient maturation of DCs. 
 
3. PKHB1-TCL from the proof of concept to therapeutic potential 
 
As described above, the simultaneous detection of cell death, exposure and release of CRT, 
the release of HSP90, ATP and HMGB1 (in vitro), in addition to the evaluation of ICD in 
the establishment of the antitumor immune response (ex vivo) are useful for the identification 
of possible inductors of ICD. However, vaccination assays involving immunocompetent 
mice and syngeneic cancer cells are the gold standard to formally identify ICD inducers, 
because this demonstrates the tumor rejection capacity of the immunized host (Kepp et al. 
2014; Garg et al. 2015). 
 
When assessing the gold standard, here it was demonstrated that the death induced by PKHB1 
activates the antitumor immune response against lymphoma cells (L5178Y-R) and breast 
cancer cells (4T1), since it achieved to prevent tumor establishment and increase survival in 
100% and 80% of the mice respectively. 
 
This has also been reported with different agents that induce ICD and in different tumor 
models. Agents such as doxorubicin, iadurobicin and mitoxantrone in a model of colorectal 
carcinoma presented between 90 and 80% of tumor-free mice (Obeid et al. 2007). Also, in a 
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colorectal carcinoma model (MC-38), specific forms of radiotherapy induced 90% survival 
of mice (Gorin et al. 2014). The alkylating agent melphalan induced 40% of tumor-free mice 
in a melanoma model (Dudek-Perić et al. 2015). In addition, the antibody 7A7 (anti-EGFR) 
induced 50% of survival in a lung carcinoma model (D-122) (Garrido et al. 2011).  
 
However, despite the existence of the gold standard, multiple publications and reviews (Bezu 
et al. 2015)  classify different ICD-inducing agents even though their direct effectiveness in 
prophylactic vaccination trials has not been proven. For example, bleomycin is considered 
as an ICD inductor (Bezu et al. 2015), however when it was tested in vivo, no prophylactic 
vaccination trials were performed and the ex vivo assays did not demonstrate a clear 
activation of the antitumor immune response (Bugaut et al. 2013). Therefore, it is necessary 
to maintain rigorous standards to confirm that an agent induces ICD to eliminate the 
possibility of reporting "false positives" (Garg et al. 2015)  since this can be prejudicial in 
clinical practice. 
 
Also, it must be taken into account that the ability of an agent to cause ICD can´t be predicted 
even from its chemical or structural properties, since molecules as similar to each other as 
oxaliplatin and cisplatin don´t share this functional profile (Tesniere et al. 2010; Martins et 
al. 2011).  
 
3.1 Therapeutic application of ICD 
 
Overall, the results obtained in this work, which showed a powerful ex vivo and in vivo 
antitumor immune response induced by PKHB1-TCL in two tumor models with different 
characteristics such as murine lymphoma (L5178Y-R) and breast cancer (4T1) encouraged 
the idea of evaluating the treatment with PKHB1-TCL on a previously established tumor. 
This strategy can be used as a confirmatory trial of ICD inductors, to evaluate their ability to 
mediate therapeutic effects dependent on the immune system against established neoplasms 
(Kepp et al. 2014). 
 
  51 
In clinical trials, TCLs have been tested in melanoma, prostate, mesothelioma, ovarian and 
colorectal cancer (Chiang, Coukos, and Kandalaft 2015). These TCLs are usually produced 
by radiation, repeated freezing and thawing, among others. In this thesis work it was 
demonstrated that the activation of CD47 by PKHB1, which has been reported to effectively 
induce cell death in different types of cancer (A.-C. Martinez-Torres et al. 2015; Denèfle et 
al. 2016a), including cells from refractory patients (A.-C. Martinez-Torres et al. 2015; 
Denèfle et al. 2016a), can provide an immunogenic TCL that is capable of promoting an 
antitumor immune response, even in the absence of adjuvants. 
 
Interestingly, when using PKHB1-TCL on established tumors of murine lymphoma and 
breast cancer, it was observed that tumor volume began to decrease 7 days after the first 
administration of PKHB1-TCL both in the lymphoma model and for the breast cancer model, 
reaching tumor regression on day 28 and 23 respectively. This waiting time corresponds to 
the time necessary for the T cells to expand and activate an antitumor immune response 
(Kaech, Wherry, and Ahmed 2002). Other types of TCL have been able to induce tumor 
regression, increasing the survival rate in patients with melanoma and prostate cancer 
(Chiang, Coukos, and Kandalaft 2015); however, they do so only in combination with 
adjuvants, as in the case of CpG oligodeoxynucleotides, which are TLR9 agonists (Anhua 
Wu 2007). It is important to note that the immunogenicity of PKHB1-TCL was found even 
in the absence of adjuvants, which have also been proved to be important to promote 
immunological memory. 
 
4. CD47-ICD and immunological memory 
 
The perspectives for cell therapy against cancer are based on the development of T cell 
responses, resulting in effective rejection of the tumor and long-term protection (Henry et al. 
1999; Farkona, Diamandis, and Blasutig 2016). From this fact, the induction of ICD is a 
potential strategy capable of inducing a long-term protection since it induces the activation 
of the adaptive immune response, through the activation of T lymphocytes. 
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Recently, it was shown by our group that PKHB1 treatment in tumor-bearing mice induced 
long-term tumor prevention in 90% of the mice that had complete tumor regression 
(Uscanga‐Palomeque et al. 2018a). Here it was shown that PKHB1-TCL-treatment induces 
long-term immunological memory against murine lymphoma and breast cancer cells, as 
100% of mice in remission after treatment with PKHB1-TCL survived after re-challenge 
with L5178YR or 4T1 cells, respectively. This underlines the immunogenicity of cell death 
mediated by CD47, when a CD47 agonist peptide or CD47-dead cells are administered. This 
long-lasting immunological memory has also been promoted by a TCL obtained by repeated 
freezing and thawing and glioma cells treated with radiation, where almost 100% survival 
was observed (Belmans et al. 2017). 
 
Although immunotherapy with pulsed DCs, primed T lymphocytes or CAR-T cells is the 
main approach used to stimulate antitumor immune responses, it was shown here that the 
crude TCL obtained from treatment with PKHB1 is capable of inducing tumor regression in 
the 80 % of the mice, while preventing the establishment of the tumor in 100% of the re-
challenged mice that survived after treatment with PKHB1-TCL. Interestingly all of these 
occurs similarly in two clearly different tumor models (L5178Y-R and 4T1). 
 
5. CD47 activation by agonist peptides: an ideal ICD strategy? 
 
According to the different trends in the fields of ICD, immunology, immunosurveillance, 
inflammation and cancer therapy in the last decade, a list of properties of an ideal ICD 
inductor were proposed, which enhance its application in clinical practice (Krysko et al. 
2012). Therefore, the evaluation of these characteristics in CD47-ICD, is important to 
determine which properties it possess, and which ones are still to be determined.  
 
First, an ideal ICD inductor must be an efficient inducer of apoptosis or other types of cell 
death, in doses that can be used preclinically or clinically without substantial toxicities or 
side effects. In this regard, it has been shown that PKHB1 induces regulated cell death in 
different types of cancer cells (A.-C. Martinez-Torres et al. 2015; Denèfle et al. 2016b; 
Uscanga‐Palomeque et al. 2018b), and it has been determined that PKHB1 treatment does 
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not induce side effects in immunodeficient mice (A. C. Martinez-Torres et al. 2015), in the 
same way, no damage is observed in different vital organs, and does not affect the percentage 
of peripheral blood leukocytes in immunocompetent mice (Uscanga‐Palomeque et al. 
2018b). 
 
Second, an ideal ICD inductor must be capable of inducing the emission of multiple types of 
DAMPs, which ensure the immune system sensitization, promoting the establishment of the 
antitumor immune response. In this work, it was determined that PKHB1 effectively induces 
the exposure and release of different DAMPs, such as CRT, HSP90, ATP and HMGB1, and 
that CD47-ICD also activates the antitumor immune response (ex vivo). 
 
Third, an ideal ICD inductor should not be susceptible to drug efflux channels, in this sense, 
the PKHB1 peptide is not sensitive to these resistance mechanisms because it depends on the 
binding with CD47 and not on its entry into the cell. 
 
In addition, since ER stress is fundamental for the ICD induction, as it activates robust pro-
death signaling, an ideal ICD inductor must be able to induce ER stress, which would 
improve the traffic of DAMPs and increase its emission. One of the main ways to induce ER 
stress is the depletion of Ca2+ reserves, which can initiate stress responses such as the 
unfolded protein response (UPR), which involves the activation of different pathways, by 
phosphorylation of PERK, IRE1a, and the transcription initiator factor eIF2a as well as the 
cleavage of ATF-6 (Bravo et al. 2013). 
In this sense, it has been observed that PKHB1 treatment in CLL cells induces a sustained 
Ca2+ release and ER morphological changes (A. C. Martinez-Torres et al. 2015). However, 
other characteristics ares still to be elucidated, such as the activation of the UPR that confirm 
the ER stress induced by the PKHB1 treatment. 
 
On the other hand, during cancer microevolution, cancer cells can acquire mutations such as 
caspase and BAX deletion among others, that could prevent the activation of signaling 
pathways of danger (Panaretakis et al. 2009; Krysko et al. 2012). Therefore, an ideal ICD 
inducer must overcome as many of these mutations as possible. 
  54 
It has been reported that PKHB1 is able to induce RCD in cells with dysfunctional p53 and 
resistant to conventional treatments (A. C. Martinez-Torres et al. 2015), also in this work was 
observed that PKHB1 is able to induce ICD in MCF-7 cells which present a deletion of 
caspase 3. Interestingly, the RCD induction by CD47-activation has been reported in 
different cancer cell lines as a caspase-independent mechanism (A. C. Martinez-Torres et al. 
2015), this could overcome mechanisms of immunogenic cell death resistance by cancer cells 
(Krysko et al. 2012). However, it is necessary to know the mechanism of DAMPs release in 
the death induced by PKHB1 in order to predict its effect in cells with mutations in this ICD 
pathway. 
 
Finally, an ideal ICD inductor must be capable of inhibiting the activation of 
proinflammatory transcription factors in order to induce tumor regression. At the same time, 
an ideal inducer of ICD should not have suppressive or inhibitory effects on immune cells 
(Th1 cells, cytotoxic T cells, DCs, among others) since they are necessary for the antitumor 
immune response establishment. Conversely, it is crucial for an ideal ICD inducer to be able 
to inhibit immunosuppressive responses, such as those mediated by tumor-associated 
macrophages (TAM, mainly M2 phenotype), myeloid-derived suppressor cells (MDSC) and 
regulatory T cells, among others (Krysko et al. 2012). 
From this point of view, it has been reported that PKHB1 induces selective RCD of tumor 
cells, since it does not affect non-tumor B cells of patients with CLL (A. C. Martinez-Torres 
et al. 2015), in addition it has been observed that it is not cytotoxic to human or murine 
PBMCs, nor to cells of primary and secondary murine lymphoid organs. 
 
As for the functions of CD47 within the immune system, in addition to functioning as a "don´t 
eat me" signal (Matozaki et al. 2009), CD47 has been reported as a key piece in the 
contraction process and resolution of the immune response in humans and mice, and in the 
differentiation of memory lymphocytes (Van et al. 2012). In addition, it has been reported 
that CD47 may be involved in the activation signals of T lymphocytes (Reinhold et al. 2002; 
Rebres et al. 2001) and in the homeostasis of regulatory T lymphocytes (Pandiyan and 
Lenardo 2008). 
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That is why the use of CD47 agonist peptides for the induction of ICD is a promising 
therapeutic strategy, since it presents most of the characteristics of an ideal ICD-inductor 
agent. 
 
In summary; 
 
• PKHB1 induces an atypical type of RCD in a large group of tumor cells, even in cells 
with mutations that make them resistant to conventional therapies. 
• CD47-ICD causes the exposure and release of different DAMPs, which induce the 
establishment of the specific antitumor immune response. 
• PKHB1 is not susceptible to drug efflux channels, since it binds to a transmembrane 
receptor, usually overexpressed by cancer cells, to induce ICD. 
• PKHB1 does not seem to affect non-tumor cells, as it has been demonstrated to spare 
immune system cells and to maintain vital organs in mice terated with this agent.  
 
For all of the above, this work evidences the promising use of CD47-activation for the 
induction of ICD. Furthermore, the results obtained from this thesis support the CD47 point 
of view that has been poorly exploited, where instead of seeing it as an enemy, we can begin 
to see it as a good friend. 
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16. CONCLUSIONS 
 
 
From the results obtained in the present thesis work we can conclude that the treatment with 
PKHB1 induces cell death and DAMPs’ release in lymphoma and breast cancer cells. Also, 
CD47-ICD is able to induce the antitumor immune system activation ex vivo through the 
maturation of dendritic cells and the activation of specific T cells responses. Furthermore, 
the gold standard was confirmed for CD47-ICD in lymphoma and breast cancer tumor 
models. Additionally, it was observed that CD47-ICD induces the tumor regression in both 
tumor models as a therapeutic antitumor strategy. Finally, it was observed for first time that 
CD47-ICD is able to induce a long-lasting antitumor immunity.  
The results obtained in this work provide the evidence of a new ICD inductor for lymphoma 
and breast cancer cells and highlight a new approach of CD47 agonist peptides, which could 
induce ICD in others cancer cells.  
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17. PERSPECTIVES 
 
• To assess the effect of the treatment with PKHB1 in a murine model of breast cancer 
(4T1).  
• To determine which cellular organelles are involved in the cell death induced by 
CD47 activation. 
• To determine the mechanism of DAMPs’ release by PKHB1 treatment in cancer cells. 
• To determine the molecular characteristics of the cell death induced by PKHB1, since 
it seems to induce a conserved immunogenic death. 
• To analyze the combinatorial effect of PKHB1 and chemotherapies in vitro and in 
vivo. 
• To evaluate the importance of CD47 in the cancer biology. 
• To evaluate the effect of CD47 agonist peptides on the immune system cells (cell 
death, activation, migration, etc.). 
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logistics responsible, 2016-2017. 
• 2nd Place in the State Contest "II Creative Young and Inventors". Institute of 
Innovation and Technology Transfer of Nuevo León and the National Council of 
Science and Technology Northeast Delegation, 2014. 
 
Professional experience: 
 
• Clinical Laboratory Technician: Biomedical and Biotechnological Developments of 
México (DEBBIOM, April 2012-July 2017). Activities: taking blood samples and 
vital signs, processing samples (protection of plasma, antidoping and pregnancy 
tests), application of good clinical practices / documentation. 
• Clinical Laboratory Technician: U.A.N.L. School of Biological Sciences, central 
teaching laboratory of the Bsc. L.B.G. (August 2013-January 2016). Activities: 
administration of the laboratory, support in the handling of equipment for teaching 
practices, preparation of maintenance programs and operating manuals. 
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• Clinical Laboratory Technician: Medical and Surgical Center "San Bernabé" 
(September 2012-February 2013). Activities: responsible for laboratory: taking, 
processing and reporting of blood and bacteriological samples; preparation of culture 
media and equipment maintenance. 
 
Publications: 
 
Scientific articles on Indexed Journals JCR 
• Uscanga-Palomeque AC, Calvillo-Rodríguez KM, Gómez-Morales L, Lardé E, 
Denèfle T, Caballero-Hernández D, Merle-Béral H, Susin SA, Karoyan P, 
Martínez-Torres AC*, Rodríguez-Padilla C*. CD47 agonist peptide PKHB1 
induces immunogenic cell death in T-cell acute lymphoblastic leukemia cells. 
Cancer Sci. 2019;110(1):256-268.  
•    Martínez-Torres AC*, Calvillo-Rodríguez KM*, Uscanga-Palomeque AC, 
Gómez Morales L, Mendoza-Reveles R, Caballero-Hernández D, Karoyan P, 
Rodríguez-Padilla C. PKHB1-tumor cell lysate induces antitumor immune 
system stimulation and tumor regression in syngeneic mice with tumoral T 
lymphoblasts. Journal of Oncology. https://doi.org/10.1155/2019/9852361.  
• Calvillo-Rodríguez KM*, Martínez-Torres AC*, Uscanga-Palomeque AC, 
Gómez-Morales L, Karoyan P, Rodríguez-Padilla C. PKHB1 induces 
immunogenic cell death in breast cancer cells. In preparation.   
 
Scientific Articles in Arbitrated Journals 
• Kenny M. Calvillo-Rodriguez, Ashanti C. Uscanga-Palomeque, Luis Gomez-
Morales, Diana E. Caballero-Hernandez, Philippe Karoyan, Cristina Rodriguez-
Padilla, Ana C. Martinez-Torres. PKHB1 induces tumor regresion through regulated 
cell death and stimulation of the immune system. RCFB, Ed. Esp. 2, pg. 68. 2018. 
• Ashanti C. Uscanga-Palomeque, Kenny M. Calvillo-Rodriguez, Luis Gomez-
Morales, Diana E. Caballero-Hernandez, Philippe Karoyan, Cristina Rodriguez-
Padilla, Ana C. Martinez-Torres. The CD47 agonist peptide, PKHB1 induces 
immunogenic cell death in acute T-cell lymphocytic leukemia cells. RCFB, Ed. Esp. 
2, pg. 39. 2018. 
• Uscanga-Palomeque, A., Martínez-Torres, AC, Calvillo-Rodríguez, KM, Gómez-
Morales, L., Caballero-Hernández, DE & Rodríguez-Padilla, C. PKHB1 induces 
tumor regression through regulated cell death and stimulation of the immune system. 
XXIX National Congress of Research in Medicine. Monterrey, México, October 4-7. 
 
Presentations: 
 
Posters 
• Activation of CD47 by the peptide PKHB1: a promising treatment against leukemia 
in the "21 State Meeting of Health Research", Monterrey, México, 2018. 
• CD47 agonist peptide, PKHB1, induces selective cell death in leukemia cell lines and 
induces tumor regression in vivo, in the congress "Young Researchers In Life 
Sciences" Paris, France, 2018. 
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• PKHB1 induces tumor regression through regulated cell death and stimulation of the 
immune system. "V National Symposium of Pharmaceutical Sciences and 
Biomedicine and III National Symposium of Applied Microbiology", Monterrey, 
México, 2018. 
• The tumor lysate obtained by PKHB1 induces the immune system activation and 
tumor regression. "VI National Symposium of Pharmaceutical Sciences and 
Biomedicine and IV National Symposium of Applied Microbiology", Monterrey, 
México, 2019. 
• TSP1-mimetic peptide PKHB1 induces immunogenic cell death in T cell leukemia. 
"Young Researchers In Life Sciences" Paris, France, 2019. 
• The activation of CD47 in breast cancer stimulates the antitumor immune response 
by inducing immunological memory. "6th CTR Scientific-Expo", Monterrey, 
México, 2019. 
 
Oral presentations 
• Errors in the preanalytical phase of the clinical laboratory. Introductory course of 
sampling (1CITM) by the Student Society of Chemicals Bacteriologists 
Parasitologists of the School of Biological Sciences, 2016. 
• Analysis of the cytotoxic and antitumor effect induced by the activation of CD47 in 
the cell line L5178Y-R. Meeting of Young Researchers, Center for 
Internationalization, UANL. Monterrey, México, 2017. 
• CD47 agonist peptide, PKHB1, induces selective cell death in leukemia cell lines and 
induces tumor regression in vivo. "European Workshops on Cell Death", Fuggi, Italy 
2018. 
• The CD47 agonist peptide, PKHB1 induces immunogenic cell death in acute T-cell 
lymphocytic leukemia cells, in the "V National Symposium of Pharmaceutical 
Sciences and Biomedicine and III National Symposium of Applied Microbiology", 
Monterrey, México, 2018. 
• The activation of CD47 in breast cancer stimulates the antitumor immune response 
by inducing immunological memory. "VI National Symposium of Pharmaceutical 
Sciences and Biomedicine and IV National Symposium of Applied Microbiology", 
Monterrey, México, 2019. 
 
Additional courses: 
 
• Animal models for research laboratories. UANL, School of Biological Sciences, 
2017. 
• 8th International Symposium on Immunopathogenesis in Cancer and Infectious 
Diseases. UANL, School of Biological Sciences, November 2015. 
• Cardio-pulmonary resuscitation. Biomedical and biotechnological developments 
Monterrey, 2014. 
• Management of Hazardous Biological-Infectious Waste, module 1 basic security. 
School of Biological Sciences, COBBIO, 2014. 
• Prevention of infections in health personnel. Faculty of Medicine, UANL, 2012. 
• 6th International Quality Control Cycle. IFCC. BIO-RAD. (Videoconferences). 
Doctors Hospital, Monterrey, Nuevo León, 2012. 
